Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs and pharmaceutical companies. To learn more about our organization, visit our website at: www.labcorp.com.

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (dollars in millions)</th>
<th>Adjusted Earnings Per Share Excluding Amortization (dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>$5.00</td>
<td>$5.24</td>
</tr>
<tr>
<td>2010</td>
<td>$5.54</td>
<td>$5.98</td>
</tr>
<tr>
<td>2011</td>
<td>$5.67</td>
<td>$6.37</td>
</tr>
<tr>
<td>2012</td>
<td>$5.81</td>
<td>$6.82</td>
</tr>
<tr>
<td>2013</td>
<td>$6.00</td>
<td>$6.95</td>
</tr>
</tbody>
</table>

5-Year CAGR of 5.2%  
5-Year CAGR of 7.2%
OUR FIVE STRATEGIC PILLARS

2 Enhance IT capabilities to improve physician and patient experience

4 Scientific innovation at appropriate pricing

We will be a trusted knowledge partner to stakeholders, leading to growth in our business and continued creation of shareholder value. We will achieve this mission by continuing to execute our five pillar strategy.
1. Deploy capital to investments that enhance our business and return capital to shareholders.

3. Continue to improve efficiency to offer the most compelling value in laboratory services.

5. Develop knowledge services.
As I reflect on the operating environment for LabCorp in 2013 and beyond, I might sum up my thoughts by paraphrasing the writer and scientist Isaac Asimov: continuing, inevitable change is the dominant factor in healthcare today. No sensible decision can be made any longer without taking into account not only the world as it is, but the world as it will be.

The world as it will be in healthcare will involve a relentless drive to improve quality, reduce costs, provide care in the lowest acuity site and reward good outcomes. Through disciplined focus on our mission – to be a trusted knowledge partner for our stakeholders – we have positioned LabCorp to succeed in this continually changing environment. In fiscal 2013 we made great progress toward fulfilling that mission through execution of our five-pillar strategy.

David P. King,
Chairman and Chief Executive Officer
First Pillar:
Deploy capital to investments that enhance our business and return capital to shareholders.

The 2012 acquisition of MEDTOX Scientific was an important addition to our capabilities in toxicology and pain management testing, and in 2013 solid growth in these businesses contributed to strong volume trends for the year. MEDTOX is the latest of several successful acquisition integrations, including Genzyme Genetics, Clearstone Central Laboratories, Orchid Cellmark and Monogram Biosciences. We remain focused on identifying promising acquisition opportunities and expect that acquisitions will remain an attractive way to expand our test menu and geographic footprint for the next several years.

We now do business in more than 40 countries, and we evaluate expansion opportunities with an increasingly global perspective. The acquisition of Orchid Cellmark brought LabCorp a strong presence in forensic testing in the UK, and the addition of Clearstone Central Laboratories extended our footprint in the clinical trials central laboratory market to key Asian geographies – China, Japan and Singapore. We will continue to seek international opportunities that require modest capital investment, present attractive growth profiles and allow us to leverage our core competencies.

Share repurchase, our vehicle for returning capital to shareholders, increased in fiscal 2013 to approximately $1 billion, representing 10.4 million LabCorp shares. In early 2013, we announced our goal to reach a target leverage ratio of 2.5 times debt-to-EBITDA over time, and our 2013 repurchase activity brought us near this objective. Over the last decade, LabCorp has repurchased nearly 77 million shares of stock at an average price of approximately $71, and we have strategically deployed our free cash flow between acquisitions and share repurchase over this time. We expect to continue to deploy capital in a balanced manner between these two objectives.

Second Pillar:
Enhance IT capabilities to improve physician and patient experience.

IT competencies are key to delivering knowledge to our customers, so they remain an important priority for LabCorp. LabCorp Beacon® is an end-to-end platform that provides the framework for a number of innovative IT products.

For example, LabCorp Beacon®: Analytics helps clients better manage practice and population health data. Supplemented with insights derived from our extensive patient database, LabCorp Beacon: Analytics helps physicians unify the

1 We now provide reproductive genetic testing services under the name Integrated Genetics and oncology genetic testing services under the name Integrated Oncology.
multiple components of population health management, providing primary care physicians complete access to their patients’ healthcare pictures, rules for monitoring gaps in care and reporting that addresses more than 600 quality measures. LabCorp Beacon: Analytics is part of the comprehensive LabCorp Beacon platform that helps providers reduce costs, improve outcomes and enhance patient satisfaction.

Third Pillar: 
Continue to improve efficiency to offer the most compelling value in laboratory services. 
To maintain our position as the most efficient provider, we regularly evaluate our processes, platforms, technologies, robotics, LEAN strategies and rationalization programs. The successful deployment of our Propel™ robot at our Powell Center for Esoteric Testing in Burlington, North Carolina, is an example of how we use technology and innovation to improve performance. Propel now splits and sorts most of the testing volume in our Atlantic division, automating specimen processing, increasing throughput and accuracy, and reducing turnaround time.

In 2013, we opened a state-of-the-art, 147,000-square-foot facility in Phoenix, Arizona, to consolidate a number of our facilities located in the Western United States. We continue to evaluate all opportunities to improve efficiency through disciplined management and control of expenses.

Fourth Pillar: 
Scientific innovation at appropriate pricing. 
We continue to be on the cutting edge of scientific innovation: in 2013 alone, we introduced 152 new tests and enhanced our menu across several testing disciplines.

I want to highlight BRCAssure™, a suite of tests that identify patients with BRCA mutations who are at increased risk for breast, ovarian and other cancers. The majority of individuals with hereditary breast and ovarian cancer syndrome, as well as a significant percentage of those diagnosed with breast cancers, exhibit mutations of the BRCA1 and BRCA2 genes, and LabCorp’s BRCA test menu includes a comprehensive panel of BRCA1/2 complete gene sequence analysis and deletion/duplication testing. Once a mutation is identified, family members can be tested for the known mutations using the BRCAssure BRCA1 or BRCAssure BRCA2 Targeted Analysis tests. Through this expansion in our test menu, we continue to show our commitment to Women’s Health testing and personalized medicine.

What we believe differentiates LabCorp’s BRCA offering from our competitors is our comprehensive suite of services to assist doctors and patients in ordering the test, assessing insurance coverage and understanding the results. Our Care Coordination preauthorization service assists patients who request the test in understanding their insurance coverage and financial responsibility. Our 123 board-certified genetic counselors – which we believe is the world’s largest complement of these highly skilled professionals – help doctors and patients analyze, assess and interpret the test results. This is a concrete example of how we are implementing our mission to be a trusted knowledge partner to multiple healthcare stakeholders.

In addition to our commitment to Women’s Health, we continue to enhance our test menu in other important areas, particularly cancer diagnostics. Our next-generation sequencing (NGS) multi-gene oncology panel, IntelliGEN™, provides an assessment of targetable mutations within a panel profile of 50 cancer genes known to be involved in the development, progression and treatment of cancers – including lung, colon and liver tumors. With our NGS capabilities, LabCorp continues to lead the industry in developing highly sensitive and cost-effective ways of providing diagnostically significant information.

Fifth Pillar: 
Develop knowledge services. 
As demonstrated above, our mission to be a knowledge partner to all healthcare stakeholders cuts across each pillar of our strategy. Within the fifth pillar specifically, BeaconLBS® addresses a growing need for guidance in ordering tests and optimization of laboratory utilization. A wholly owned LabCorp subsidiary, BeaconLBS brings together the central roles of the laboratory, the healthcare provider and the health plan to deliver high-quality, efficient and affordable laboratory services for improved patient care. Its decision support capabilities are designed to help physicians select the appropriate test, test application and
Providing End-to-End Solutions for Our Customers

Our knowledge services now go well beyond the testing of samples and the delivery of results, as we provide end-to-end lab solutions for our customers. Our capabilities include population health management tools, data analytics, decision support programs, personalized medicine and companion diagnostic testing, and genetic counseling.

In 2013, UnitedHealthcare selected BeaconLBS to implement its product in Florida. We expect implementation of this agreement to occur in 2014, and we are excited about the opportunity for BeaconLBS to demonstrate its value to payers, physicians and patients.

Our knowledge services now go well beyond the testing of samples and the delivery of results, as we provide end-to-end lab solutions for our customers. Our capabilities include population health management tools, data analytics, decision support programs, personalized medicine and companion diagnostic testing, and genetic counseling. Over time, we intend to add mobile health, connected devices and care in the home to our range of product offerings. All of these tools will confirm our critical position in the emerging healthcare value chain.

Sound Financial Performance

Challenges often accompany disruptive marketplace change, and this dynamic was evident in fiscal 2013. The major headwinds were unfavorable government payment reductions and reimbursement challenges related to our molecular pathology testing; together these factors generated a headwind that we estimate reduced our adjusted operating earnings by more than $100 million. Given that, LabCorp delivered another strong financial performance, generating revenue growth of 2.4 percent, to $5.8 billion, and Adjusted Earnings Per Share Excluding Amortization of $6.95. LabCorp also generated solid Operating Cash Flow of $819 million and Free Cash Flow of $617 million, almost all of which we returned to shareholders through share repurchase.

Focused on Long-Term Opportunities

We are committed to generating durable, sustainable, profitable growth. We are in this business for the long haul and have confidence that our knowledge partnership mission and our five-pillar strategy will lead to success. Fiscal 2013 was a challenging year in many respects, and some of those challenges are likely to remain through fiscal 2014. With this in mind, we are committed to gaining market share, improving growth in our esoteric businesses, diversifying our revenue base and driving greater operational efficiency and cost reductions across our businesses. We are privileged to have over 34,000 employees who care for patients every day, and I am deeply grateful to them for their extraordinary efforts. It is an honor beyond description to lead them.

The continuing, inevitable change in healthcare requires LabCorp to continually and inevitably change. That said, we are committed to leading our industry and the healthcare system into the world that will be. We are privileged to have the opportunity and grateful to you, our shareholders and stakeholders, for your continued support.

Sincerely,

Dave King
Chairman and Chief Executive Officer

---

2 Adjusted Earnings Per Share Excluding Amortization is calculated by excluding the effects of the impact of restructuring and other special charges and amortization expense from GAAP diluted earnings per share. Free cash flow represents cash flows from operations less capital expenditures. For a reconciliation of non-GAAP financial measures, please refer to slides 7-9 of the Company’s 8-K filed on February 7, 2014.
Table of Contents

Selected Financial Data ........................................... 6
Management’s Discussion and Analysis
of Financial Condition and Results of Operations ......... 8
Report of Management on Internal Control
Over Financial Reporting ........................................... 22
Report of Independent Registered
Public Accounting Firm ........................................... 23
Consolidated Balance Sheets ............................. 24
Consolidated Statements of Operations ................. 25
Consolidated Statements of Comprehensive Earnings .. 25
Consolidated Statements of Changes in
Shareholders’ Equity ........................................... 26
Consolidated Statements of Cash Flows ................. 27
Notes to Consolidated Financial Statements ......... 28
Shareholder and Company Information ............. 53
The selected financial data presented below under the captions “Statement of Operations Data” and “Balance Sheet Data” as of and for the five-year period ended December 31, 2013 are derived from consolidated financial statements of the Company, which have been audited by an independent registered public accounting firm. This data should be read in conjunction with the accompanying notes, the Company’s consolidated financial statements and the related notes thereto, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” all included elsewhere herein.

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2013 (a)</th>
<th>2012 (b)</th>
<th>2011 (c, d)</th>
<th>2010 (e)</th>
<th>2009 (f)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Statement of Operations Data:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net sales</td>
<td>$5,808.3</td>
<td>$5,671.4</td>
<td>$5,542.3</td>
<td>$5,003.9</td>
<td>$4,694.7</td>
</tr>
<tr>
<td>Gross profit</td>
<td>2,223.2</td>
<td>2,249.7</td>
<td>2,274.7</td>
<td>2,097.8</td>
<td>1,970.9</td>
</tr>
<tr>
<td>Operating income</td>
<td>990.9</td>
<td>1,023.5</td>
<td>948.4</td>
<td>978.8</td>
<td>935.9</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>573.8</td>
<td>583.1</td>
<td>519.7</td>
<td>558.2</td>
<td>543.3</td>
</tr>
<tr>
<td>Basic earnings per common share</td>
<td>$6.36</td>
<td>$6.09</td>
<td>$5.20</td>
<td>$5.42</td>
<td>$5.06</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>$6.25</td>
<td>$5.99</td>
<td>$5.11</td>
<td>$5.29</td>
<td>$4.98</td>
</tr>
<tr>
<td>Basic weighted average common shares outstanding</td>
<td>90.2</td>
<td>95.7</td>
<td>100.0</td>
<td>103.0</td>
<td>107.4</td>
</tr>
<tr>
<td>Diluted weighted average common shares outstanding</td>
<td>91.8</td>
<td>97.4</td>
<td>101.8</td>
<td>105.4</td>
<td>109.1</td>
</tr>
</tbody>
</table>

| Balance Sheet Data: | | | | | |
| Cash and cash equivalents, and short-term investments | $404.0 | $466.8 | $159.3 | $230.7 | $148.5 |
| Goodwill and intangible assets, net | 4,594.8 | 4,569.4 | 4,302.5 | 4,275.4 | 3,239.3 |
| Total assets | 6,965.9 | 6,795.0 | 6,111.8 | 6,187.8 | 4,837.8 |
| Long-term obligations(g) | 3,000.4 | 2,655.0 | 2,221.0 | 2,188.4 | 1,394.4 |
| Total shareholders’ equity | 2,491.3 | 2,717.4 | 2,503.5 | 2,466.3 | 2,106.1 |

(a) During 2013, the Company recorded net restructuring charges of $21.8. The charges were comprised of $15.4 in severance and other personnel costs and $9.5 in facility-related costs primarily associated with facility closures and general integration initiatives. These charges were offset by the reversal of previously established reserves of $0.7 in unused severance and $2.4 in unused facility-related costs.

(b) During 2012, the Company recorded net restructuring charges of $25.3. The charges were comprised of $16.2 in severance and other personnel costs and $19.6 in facility-related costs primarily associated with the ongoing integration activities of Orchid and the Integrated Genetics business (formerly Genzyme Genetics) and costs associated with the previously announced termination of an executive vice president. These charges were offset by the reversal of previously established reserves of $6.3 in unused severance and $4.2 in unused facility-related costs. As part of the Clearstone integration, the Company also recorded a $6.9 loss on the disposal of one of its European subsidiaries in Other, net under Other income (expenses) during 2012. In addition, the Company recorded $6.2 in accelerated amortization relating to the termination of a licensing agreement.
(c) During 2011, the Company recorded net restructuring charges of $44.6. Of this amount, $27.4 related to severance and other personnel costs, and $22.0 primarily related to facility-related costs associated with the ongoing integration of certain acquisitions including Genzyme Genetics and Westcliff Medical Laboratories, Inc. ("Westcliff"). These charges were offset by restructuring credits of $4.8 resulting from the reversal of unused severance and facility closure liabilities. In addition, the Company recorded fixed assets impairment charges of $18.9 primarily related to equipment, computer systems and leasehold improvements in closed facilities. The Company also recorded special charges of $14.8 related to the write-off of certain assets and liabilities related to an investment made in prior years, along with a $2.6 write-off of an uncollectible receivable from a past installment sale of one of the Company’s lab operations.

(d) Following the closing of its acquisition of Orchid in mid-December 2011, the Company recorded a net $2.8 loss on its divestiture of certain assets of Orchid’s U.S. government paternity business, under the terms of the agreement reached with the U.S. Federal Trade Commission. This non-deductible loss on disposal was recorded in Other Income and Expense in the Company’s Consolidated Statements of Operations and decreased net earnings for the twelve months ended December 31, 2011 by $2.8.

(e) During 2010, the Company recorded net restructuring charges of $5.8 primarily related to workforce reductions and the closing of redundant and underutilized facilities. In addition, the Company recorded a special charge of $6.2 related to the write-off of development costs incurred on systems abandoned during the year.

The Company incurred approximately $25.7 in professional fees and expenses in connection with the acquisition of Genzyme Genetics and other acquisition activity, including significant costs associated with the Federal Trade Commission’s review of the Company’s purchase of specified net assets of Westcliff. These fees and expenses are included in selling, general and administrative expenses for the year ended December 31, 2010.

The Company also incurred $7.0 of financing commitment fees (included in interest expense for the year ended December 31, 2010) in connection with the acquisition of Genzyme Genetics.

(f) During 2009, the Company recorded net restructuring charges of $13.5 primarily related to the closing of redundant and underutilized facilities.

In October 2009, the Company received approval from its Board of Directors to freeze any additional service-based credits for any years of service after December 31, 2009 on the defined benefit retirement plan (the “Company Plan”) and the nonqualified supplemental retirement plan (the “PEP”). As a result of the changes to the Company Plan and PEP which were adopted in the fourth quarter of 2009, the Company recognized a net curtailment charge of $2.8 due to remeasurement of the PEP obligation at December 31, 2009 and the acceleration of unrecognized prior service for that plan. In addition, the Company recorded favorable adjustments of $21.5 to its tax provision relating to the resolution of certain state income tax issues under audit, as well as the realization of foreign tax credits.

In connection with the Monogram Biosciences acquisition, the Company incurred $2.7 in transaction fees and expenses in the third quarter of 2009.

(g) Long-term obligations primarily include the Company’s zero-coupon convertible subordinated notes, 5 1/2% senior notes due 2013, 5 5/8% senior notes due 2015, 3 1/8% senior notes due 2016, 2 1/2% senior notes due 2017, 2 1/2% senior notes due 2018, 4 5/8% senior notes due 2020, 3 3/4% senior notes due 2022, 4% senior notes due 2023, term loan, revolving credit facility and other long-term obligations. The accreted balance of the zero-coupon convertible subordinated notes was $110.8, $130.0, $135.5, $286.7 and $292.2 at December 31, 2013, 2012, 2011, 2010 and 2009, respectively. The balance of the 5 1/2% senior notes, including principal and unamortized portion of a deferred gain on an interest rate swap agreement, was $0.0, $350.0, $350.5, $350.9 and $351.3 at December 31, 2013, 2012, 2011, 2010 and 2009, respectively. The principal balance of the 5 5/8% senior notes was $250.0 at December 31, 2013, 2012, 2011, 2010 and 2009. The principal balance of the 3 1/8% senior notes was $325.0 at December 31, 2013, 2012, 2011 and 2010, and $0.0 for 2009. The principal balance of the 4 5/8% senior notes was $600.0 at December 31, 2013, 2012, 2011 and 2010 and $0 for 2009. The principal balances of the 2 1/5% and 3 3/4% senior notes were $500.0 each at December 31, 2013 and 2012 and $0.0 for all other years presented. The principal balances of the 2 1/2% and 4% senior notes were $400.0 and $300.0, respectively, at December 31, 2013 and $0.0 for all other years presented. The term loan was $0.0, $0.0, $0.0, $375.0 and $425.0 at December 31, 2013, 2012, 2011, 2010 and 2009, respectively. The revolving credit facility was $0.0, $0.0, $560.0, $0.0 and $75.0 at December 31, 2013, 2012, 2011, 2010, and 2009, respectively. The remainder of other long-term obligations consisted primarily of capital leases and mortgages payable with balances of $14.6, $0.0, $0.0, $0.8 and $0.9 at December 31, 2013, 2012, 2011, 2010 and 2009, respectively. Long-term obligations exclude amounts due to affiliates.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

General
Net sales for 2013 increased 2.4% in comparison to 2012 on a 4.0% increase in volume and a 1.6% decrease in revenue per requisition. The Company’s acquisition of MEDTOX on July 31, 2012 increased revenue and volume by 1.6% and 2.1%, respectively, in 2013 compared to 2012 and 1.0% and 1.4%, respectively, in 2012 compared to 2011. The Company’s acquisition of Orchid in December 2011 increased revenue and volume by 1.1% and 0.3%, respectively, in 2012 compared to 2011.

During 2013, government payment reductions and molecular pathology payment issues reduced the Company’s year over year margins by approximately 150 basis points, reduced year over year revenue per requisition by approximately 2% and reduced year over year operating flow by more than an estimated $100.0. Also, growth in the Company’s toxicology business reduced 2013 year over year revenue per requisition by approximately 1%.

During 2013, the impact of weather reduced the Company’s revenues and diluted earnings per share by an estimated $12.7 and $0.07, respectively. During 2012, the impact of weather (notably from Super Storm Sandy in October 2012) reduced the Company’s revenues and diluted earnings per share by an estimated $16.0 and $0.09, respectively.

The Company has seen growth in the amount of its patient accounts receivable. A significant portion of the Company’s bad debt expense is related to accounts receivable from patients. The Company believes its current allowance for doubtful accounts is sufficient to properly record its accounts receivable at their estimated net realizable value. Should this shift towards increased patient responsibility continue, the Company may need to increase its allowance for doubtful accounts and bad debt expense in future periods.

The Company manages its operations through two reportable segments: the Clinical diagnostics laboratory segment, which includes core testing as well as genomic and esoteric testing, and the Other segment, comprised of the Company’s non-U.S. clinical diagnostic laboratory operations in Ontario, Canada, which is reviewed separately by corporate management for the purposes of allocation of resources. As mentioned above, the Clinical diagnostics laboratory segment results of operations have been negatively impacted by the reductions in payments for laboratory services, primarily from federal and state government entities. Operating results for the Other segment have declined slightly as compared to 2012, primarily due to the expansion of that segment through acquisitions not fully integrated and synergies not fully realized, as well as the impact of the stronger U.S. dollar in 2013 as compared with 2012.

Seasonality
The majority of the Company’s testing volume is dependent on patient visits to physician offices and other providers of health care. Volume of testing generally declines during the year-end holiday periods and other major holidays. In addition, volume declines due to inclement weather may reduce net revenues and cash flows. Therefore, comparison of the results of successive periods may not accurately reflect trends or results from one year to the next.

Results of Operations
(amounts in millions except Revenue Per Requisition info)

Years ended December 31, 2013, 2012, and 2011

Net Sales

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical diagnostics laboratory:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core Testing</td>
<td>$3,445.1</td>
<td>$3,246.6</td>
</tr>
<tr>
<td>Genomic and Esoteric Testing</td>
<td>$2,020.1</td>
<td>$2,089.8</td>
</tr>
<tr>
<td>Other</td>
<td>343.1</td>
<td>335.0</td>
</tr>
<tr>
<td>Total</td>
<td>$5,808.3</td>
<td>$5,671.4</td>
</tr>
</tbody>
</table>

Volume

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical diagnostics laboratory:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core Testing</td>
<td>89.9</td>
<td>86.2</td>
</tr>
<tr>
<td>Genomic and Esoteric Testing</td>
<td>31.2</td>
<td>29.9</td>
</tr>
<tr>
<td>Other</td>
<td>9.9</td>
<td>9.8</td>
</tr>
<tr>
<td>Total</td>
<td>131.0</td>
<td>125.9</td>
</tr>
</tbody>
</table>

Revenue Per Requisition

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue Per Requisition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical diagnostics laboratory:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core Testing</td>
<td>$38.31</td>
<td>$37.68</td>
</tr>
<tr>
<td>Genomic and Esoteric Testing</td>
<td>64.84</td>
<td>69.94</td>
</tr>
<tr>
<td>Other</td>
<td>34.53</td>
<td>33.94</td>
</tr>
<tr>
<td>Total</td>
<td>$44.33</td>
<td>$45.04</td>
</tr>
</tbody>
</table>

The increase in net sales for the three years ended December 31, 2013 has been driven primarily by acquisitions made in all years in both of the Company’s segments, along with growth in the Company’s managed care business and toxicology testing.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

During 2013, the impact of weather, reduced the Company’s revenues by an estimated $12.7, of which $5.3 occurred in the fourth quarter. The 2013 decline in revenue per requisition in genomic and esoteric testing is a result of a change in mix of genetic and histology testing. Histology revenue per requisition was also impacted by payment reductions on the Medicare physician fee schedule. Further, revenue per requisition also decreased due to delays in payments and denials of coverage for existing tests by some payers after implementation of new molecular pathology codes at the beginning of the year and the implementation of sequestration on April 1, 2013.

During the fourth quarter of 2012, the impact of weather reduced revenue by an estimated $16.0. The increase in net sales for the year ended December 31, 2012 as compared with 2011 was driven primarily by the MEDTOX and Orchid acquisitions and by contributions from the milder winter weather experienced in the first quarter of 2012, along with positive volume growth in genomic and esoteric testing and the Other segment, offset by volume losses sustained in the fourth quarter of 2012 due to Super Storm Sandy. Genomic and esoteric testing volume as a percentage of total volume was 23.7% in both 2012 and 2011. Volume growth for genomic and esoteric testing was primarily due to the incremental volume from Orchid as well as growth in the NuSwab® series of women’s health tests, offset by declines in histology and surgical pathology volumes. The decline in price in genomic and esoteric testing is a result of a lower mix of reproductive and histology testing.

Net sales of the Other segment were $343.1 for 2013 compared to $335.0 in 2012, an increase of $8.1, or 2.4%. Net sales of the Other segment were negatively impacted by a stronger U.S. dollar in 2013 as compared with 2012 and 2011. In Canadian dollars, net sales of the Other segment for the twelve months ended December 31, 2013, 2012 and 2011 were CN$353.2, CN$334.7 and CN$306.0, respectively.

The increase in cost of sales as a percentage of net sales in 2012 as compared to 2011 was primarily due to the impact of weather, lower margins on acquired operations that have not yet been fully integrated as well as slower volume growth.

The increase in cost of sales as a percentage of net sales in 2013 as compared with 2012 primarily due to overall growth in the Company’s volume, the impact of acquisitions, increases in labor, and the continued shift in test mix to genomic and esoteric testing which contributed to the higher cost of testing supplies.

### Selling, General and Administrative Expenses

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selling, general and</td>
<td>$1,128.8</td>
</tr>
<tr>
<td>administrative expenses</td>
<td></td>
</tr>
<tr>
<td>SGA as a % of sales</td>
<td>19.4%</td>
</tr>
</tbody>
</table>

Selling, general and administrative expenses as a percentage of net sales decreased to 19.4% in 2013 compared to 19.7% in 2012. The decrease in selling, general and administrative expenses as a percentage of net sales is primarily due to $9.9 in fees related to the MEDTOX acquisition recorded in 2012 and to efficiencies from acquired operations that are being integrated into the Company’s operating cost structure. Additionally, bad debt expense increased to 4.4% of net sales in 2013 as compared to 4.3% of net sales in 2012.

Selling, general and administrative expenses as a percentage of net sales decreased to 19.7% in 2012 compared to 20.9% in 2011. The decrease in selling, general and administrative expenses as a percentage of net sales was partially due to expense management and to efficiencies from acquired operations that were integrated into the Company’s cost structure. Additionally, bad debt expense decreased to 4.3% of net sales in 2012 as compared with 4.6% in 2011 primarily due to improved collection trends resulting from process improvement programs within the Company’s billing department and field operations. These decreases in selling, general and administrative expenses were partially offset by $9.9 in transaction fees related to the MEDTOX acquisition, mentioned above. During 2011, the Company recorded the settlement of the Hunter Labs litigation in California for $34.5 ($49.5 settlement less previously recorded reserves of $15.0) in selling, general and administrative expenses.

### Cost of Sales

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of sales</td>
<td>$3,585.1</td>
<td>$3,421.7</td>
<td>$3,267.6</td>
<td>4.8%</td>
</tr>
<tr>
<td>Cost of sales as a % of sales</td>
<td>61.7%</td>
<td>60.3%</td>
<td>59.0%</td>
<td></td>
</tr>
</tbody>
</table>
Management’s Discussion and Analysis
of Financial Condition and Results of Operations (in millions)

Amortization of Intangibles and Other Assets

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amortization of intangibles and other assets</td>
<td>$81.7</td>
<td>$86.3</td>
</tr>
</tbody>
</table>

The decrease in amortization of intangibles and other assets over the three year period ended December 31, 2013 primarily reflects the net impact of acquisitions closed during all three years offset by adjustments to the fair value of deferred acquisition payments. During 2012, the Company recorded $6.2 in accelerated amortization relating to the termination of a licensing agreement.

Restructuring and Other Special Charges

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td>Restructuring and other special charges</td>
<td>$21.8</td>
<td>$25.3</td>
</tr>
</tbody>
</table>

During 2013, the Company recorded net restructuring charges of $21.8. The charges were comprised of $15.4 in severance and other personnel costs and $9.5 in facility-related costs primarily associated with general integration activities. These charges were offset by the reversal of previously established reserves of $0.7 in unused severance and $2.4 in unused facility-related costs.

During 2012, the Company recorded net restructuring charges of $25.3. These charges were comprised of $16.2 in severance and other personnel costs and $19.6 in facility-related costs primarily associated with the ongoing integration activities of Orchid and the Integrated Genetics business and costs associated with the previously announced termination of an executive vice president. These charges were offset by the reversal of previously established reserves of $6.3 in unused severance and $4.2 in unused facility-related costs.

During 2011, the Company recorded net restructuring charges of $44.6. Of this amount, $27.4 related to severance and other personnel costs, and $22.0 primarily related to facility related costs associated with the ongoing integration of certain acquisitions including Genzyme Genetics and Westcliff. These charges were offset by restructuring credits of $4.8, resulting from the reversal of unused severance and facility closure liabilities. In addition, the Company recorded fixed assets impairment charges of $18.9 primarily related to equipment, computer systems and leasehold improvements in closed facilities. The Company also recorded special charges of $14.8 related to the write-off of certain assets and liabilities related to an investment made in prior years, along with a $2.6 write-off of an uncollectible receivable from a past installment sale of one of the Company’s lab operations.

From time to time, the Company implements cost savings initiatives. These initiatives result from the integration of recently acquired businesses and from reducing the number of facilities and employees in an effort to balance the Company’s cost of operations with current test volume trends while maintaining the high quality of its services that the marketplace demands. It is difficult to determine the nature, timing and extent of these activities until adequate planning has been completed and reviewed. The continuing economic downturn being experienced in the U.S. and globally has had an impact on the Company’s business. The Company believes that any restructuring costs which may be incurred in future periods will be more than offset by subsequent savings realized from these potential actions and that any related restructuring charges will not have a material impact on the Company’s operations or liquidity.

As part of the Clearstone integration, the Company also recorded a 6.9 loss on the disposal of one of its European subsidiaries in Other, net under Other income (expenses) during 2012.

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest expense</td>
<td>$96.5</td>
<td>$94.5</td>
</tr>
</tbody>
</table>

The increase in interest expense for 2013 as compared with 2012 is primarily due to the issuance of $700.0 of senior notes in November 2013 and $1,000.0 of senior notes in August 2012, net of the payoff of the 5.5% senior notes due 2013 and the reductions in borrowings under the Revolving Credit Facility due to paydowns with proceeds from the 2012 and 2013 issuances. This increase was also partially offset by a decrease in interest expense on the senior notes due 2020 as a result of entering into a fixed to floating interest rate swap in the third quarter of 2013.

The increase in interest expense for 2012 as compared with 2011 is primarily due to the issuance of $1,000.0 of senior notes in August 2012. This increase was partially offset by the settlement of approximately $155.1 of the zero-coupon subordinated notes during 2011. In addition, during December 2011, the Company replaced its existing term loan facility (the “Term Loan Facility”) with a new revolving credit facility (the “Revolving Credit Facility”), which is described further in “Note 11 to Consolidated Financial Statements.” The new Revolving Credit Facility had a lower effective interest rate during 2012 compared with the effective interest rate on the Term Loan Facility during 2011.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

**Equity Method Income**

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity method income</td>
<td>$16.9</td>
<td>$21.4</td>
</tr>
</tbody>
</table>

Equity method income represents the Company’s ownership share in joint venture partnerships along with equity investments in other companies in the healthcare industry. The decrease in income in 2013 compared to 2012 is primarily the result of a $2.9 increase recorded in 2012 due to the liquidation of one of its joint ventures and a decline in profitability of one of the Company’s joint venture partnerships due to a challenging business climate in its market.

The increase in income in 2012 compared with 2011 is primarily due to the Company’s share of losses during 2011 in the Cincinnati, Ohio joint venture (liquidation initiated in the second half of 2011) and the Canada, China, Singapore and Western Europe equity method investments (acquired by the Company in the second half of 2011) and the $2.9 increase in equity method income recorded in 2012, in conjunction with the liquidation of one of its joint ventures.

**Income Tax Expense**

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>$340.2</td>
<td>$359.4</td>
</tr>
<tr>
<td>Income tax expense as a % of income before tax</td>
<td>37.2%</td>
<td>38.1%</td>
</tr>
</tbody>
</table>

The effective rate for 2013 was favorably impacted by the release of a capital loss valuation allowance and recording two years of the R&D tax credit. The American Taxpayer Relief Act of 2012 was enacted in early 2013 and reinstated the R&D tax credit for 2012 and extended the credit for calendar year 2013.

The effective tax rate for 2012 was favorably impacted by a decrease in the reserve for unrecognized income tax benefits compared to 2011, partially offset by an increase in tax on the additional investment in the Company’s Canadian subsidiary. The effective tax rate for 2011 was negatively impacted by an increase in the reserve for unrecognized income tax benefits, the divestiture of certain Orchid paternity contracts, and foreign losses not tax effected.

**Liquidity, Capital Resources and Financial Position**

The Company’s strong cash-generating capability and financial condition typically have provided ready access to capital markets. The Company’s principal source of liquidity is operating cash flow, supplemented by proceeds from debt offerings. This cash-generating capability is one of the Company’s fundamental strengths and provides substantial financial flexibility in meeting operating, investing and financing needs. The Company’s senior unsecured Revolving Credit Facility is further discussed in “Note 11 to Consolidated Financial Statements.”

On November 1, 2013, the Company issued $700.0 in new senior notes pursuant to the Company’s effective shelf registration on Form S-3. The senior notes consisted of $400.0 aggregate principal amount of 2.50% Senior Notes due 2018 and $300.0 aggregate principal amount of 4.00% Senior Notes due 2023. The net proceeds were first used to repay all of the outstanding borrowings under the Company’s Revolving Credit Facility and the remainder was used for general corporate purposes.

During the third quarter of 2013, the Company entered into fixed-to-variable interest rate swap agreements for the 4.625% senior notes due 2020 with an aggregate notional amount of $600.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company’s long term debt. These derivative financial instruments are accounted for as fair value hedges of the senior notes due 2020. These interest rate swaps are included in other long term assets and added to the value of the senior notes, with an aggregate fair value of $0.0 at December 31, 2013. As the specific terms and notional amounts of the derivative financial instruments match those of the fixed-rate debt being hedged, the derivative instruments are assumed to be perfectly effective hedges and accordingly, there is no impact to the Company’s Consolidated Statements of Operations. There were no derivative instruments designated as accounting hedges in 2012.

On August 23, 2012, the Company issued $1,000.0 in new senior notes pursuant to the Company’s effective shelf registration statement on Form S-3. The new senior notes consisted of $500.0 aggregate principal amount of 2.20% Senior Notes due 2017 and $500.0 aggregate principal amount of 3.75% Senior Notes due 2022. The net proceeds were used to repay $625.0 of the outstanding borrowings under the Company’s Revolving Credit Facility. The remaining proceeds were available for other general corporate purposes.

On July 31, 2012, the Company completed its acquisition of MEDTOX for $236.4 in cash, excluding transaction fees. The acquisition was financed through borrowings from the Company’s Revolving Credit Facility and cash on hand.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

The Company has discussed its intention to increase its ratio of total debt to consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (“EBITDA”) over time from 2.0 to 1.0 as of December 2012 to 2.5 to 1.0. The Company believes that it can achieve this through the use of its Revolving Credit Facility and its ready access to debt capital markets. As of December 31, 2013, the ratio of total debt to consolidated EBITDA was 2.4 to 1.0. The Company continues to monitor the debt capital markets and, given current market conditions, believes it can readily increase its ratio of total debt to consolidated EBITDA. The Company believes that its cash from operations, in combination with cash on hand and borrowing capacity, will be sufficient to satisfy its obligations in 2014 and beyond.

**Operating Activities**

In 2013, the Company’s operations provided $818.7 of cash, reflecting the Company’s solid business results. The decrease in cash provided from operations in 2013 as compared with 2012 is primarily attributable to the delays and denials of coverage for existing tests by some payers after implementation of newly established molecular pathology codes as well as government payment reductions. These delays, denials and government reductions reduced year over year operating cash flow by more than an estimated $100.0. The Company continues to focus on efforts to increase cash collections from all payers and to generate ongoing improvements to the claim submission processes.

In 2012, the Company’s operations provided $841.4 of cash, reflecting the Company’s solid business results. The Company continued to focus on efforts to increase cash collections from all payers and to generate ongoing improvements to the claim submission processes.

**Investing Activities**

Capital expenditures were $202.2, $173.8 and $145.7 for 2013, 2012 and 2011, respectively. The increase in capital spending in 2013 was related to certain integration and cost savings initiatives started by the Company. The Company expects capital expenditures of approximately $185.0 to $205.0 in 2014. Such expenditures are expected to be funded by cash flow from operations, as well as borrowings under the Company’s Revolving Credit Facility as needed.

The Company remains committed to growing its business through strategic business acquisitions, including MEDTOX Scientific in 2012 and Orchid in 2011. These acquisitions have helped strengthen the Company’s geographic presence along with expanding capabilities in the specialty testing operations. The Company believes the acquisition market remains attractive with a number of opportunities to strengthen its scientific capabilities, grow esoteric testing capabilities and increase presence in key geographic areas.

The Company has invested a total of $2.9 over the past three years in licensing new testing technologies and had $41.0 net book value of capitalized patents, licenses and technology as of December 31, 2013. While the Company continues to believe its strategy of entering into licensing and technology distribution agreements with the developers of leading-edge technologies will provide future growth in revenues, there are certain risks associated with these investments. These risks include, but are not limited to, the failure of the licensed technology to gain broad acceptance in the marketplace and/or that insurance companies, managed care organizations, or Medicare and Medicaid will not approve reimbursement for these tests at a level commensurate with the costs of running the tests. Any or all of these circumstances could result in impairment in the value of the related capitalized licensing costs.

**Financing Activities**

On December 21, 2011, the Company entered into a Credit Agreement (the “Credit Agreement”) providing for the Revolving Credit Facility, a five-year $1,000.0 senior unsecured revolving credit facility with Bank of America, N.A., acting as Administrative Agent, Barclays Capital as Syndication Agent, and a group of financial institutions as lending parties. As part of the new Revolving Credit Facility, the Company repaid all of the outstanding principal balances of $318.8 on its existing term loan facility and $235.0 on its existing revolving credit facility. In conjunction with the repayment and cancellation of its old credit facility, the Company recorded approximately $1.0 of remaining unamortized debt costs as interest expense in the accompanying Consolidated Statements of Operations for the year ended December 31, 2011.

There were no balances outstanding on the Company’s Revolving Credit Facility at December 31, 2013 or December 31, 2012. The Revolving Credit Facility bears interest at varying rates based upon a base rate or LIBOR plus (in each case) a percentage based on the Company’s debt rating with Standard & Poor’s and Moody’s Rating Services.
The Revolving Credit Facility is available for general corporate purposes, including working capital, capital expenditures, acquisitions, funding of share repurchases and other restricted payments permitted under the Credit Agreement. The Credit Agreement also contains limitations on aggregate subsidiary indebtedness and a debt covenant that requires that the Company maintain on the last day of any period of four consecutive fiscal quarters, in each case taken as one accounting period, a ratio of total debt to consolidated EBITDA of not more than 3.0 to 1.0. The Company was in compliance with all covenants in the Credit Agreement at December 31, 2013. As of December 31, 2013, the ratio of total debt to consolidated EBITDA was 2.4.

As of December 31, 2013, the effective interest rate on the Revolving Credit Facility was 1.1%.

On November 1, 2013, the Company issued $700.0 in new senior notes pursuant to the Company’s effective shelf registration on Form S-3. The new senior notes consisted of $400.0 aggregate principal amount of 2.50% Senior Notes due 2018 and $300.0 aggregate principal amount of 4.00% Senior Notes due 2023. The net proceeds were used to repay all of the outstanding borrowings under the Company’s Revolving Credit Facility and for general corporate purposes.

The Senior Notes due 2018 and Senior Notes due 2023 bear interest at the rate of 2.50% per annum and 4.00% per annum, respectively, payable semi-annually on May 1 and November of each year, commencing on May 1, 2014.

On August 23, 2012, the Company issued $1,000.0 in new senior notes pursuant to the Company’s effective shelf registration statement on Form S-3. The new senior notes consisted of $500.0 aggregate principal amount of 2.20% Senior Notes due 2017 and $500.0 aggregate principal amount of 3.75% Senior Notes due 2022. The net proceeds were used to repay $625.0 of the outstanding borrowings under the Company’s Revolving Credit Facility. The remaining proceeds are available for other general corporate purposes.

The Senior Notes due 2017 and Senior Notes due 2022 bear interest at the rate of 2.20% per annum and 3.75% per annum, respectively, payable semi-annually on February 23 and August 23 of each year, commencing February 23, 2013.

During 2013, the Company purchased $1,015.6 of its stock representing 10.4 shares. As of December 31, 2013, the Company had remaining outstanding authorization from the Board of Directors to purchase $1,058.5 of Company common stock.

During 2013, the Company settled notices to convert $25.5 aggregate principal amount at maturity of its zero-coupon subordinated notes with a conversion value of $31.8. The total cash used for these settlements was $21.5 and the Company also issued 0.1 additional shares of common stock.

On September 12, 2013, the Company announced that for the period of September 12, 2013 to March 11, 2014, the zero-coupon subordinated notes will accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a zero-coupon subordinated note for the five trading days ended September 6, 2013, in addition to the continued accrual of the original issue discount.

On January 2, 2014, the Company announced that its zero-coupon subordinated notes may be converted into cash and common stock at the conversion rate of 13.4108 per $1,000 principal amount at maturity of the notes, subject to the terms of the zero-coupon subordinated notes and the Indenture, dated as of October 24, 2006 between the Company and The Bank of New York Mellon, as trustee and conversion agent. In order to exercise the option to convert all or a portion of the zero-coupon subordinated notes, holders are required to validly surrender their zero-coupon subordinated notes at any time during the calendar quarter beginning January 1, 2014, through the close of business on the last business day of the calendar quarter, which is 5:00 p.m., New York City time, on Monday, March 31, 2014. If notices of conversion are received, the Company plans to settle the cash portion of the conversion obligation with cash on hand and/or borrowings under the revolving credit facility.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

Credit Ratings
The Company’s debt ratings of Baa2 from Moody’s and BBB+ from Standard & Poor’s contribute to its ability to access capital markets.

Contractual Cash Obligations

<table>
<thead>
<tr>
<th>Payments Due by Period</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating lease obligations</td>
<td>$373.4</td>
<td>$132.3</td>
<td>$139.9</td>
<td>$60.2</td>
<td>$41.0</td>
</tr>
<tr>
<td>Contingent future licensing payments(a)</td>
<td>15.6</td>
<td>3.0</td>
<td>5.7</td>
<td>5.0</td>
<td>1.9</td>
</tr>
<tr>
<td>Minimum royalty payments</td>
<td>6.0</td>
<td>1.2</td>
<td>1.9</td>
<td>1.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Zero-coupon subordinated notes(b)</td>
<td>110.8</td>
<td>110.8</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Scheduled interest payments on Senior Notes</td>
<td>630.5</td>
<td>103.7</td>
<td>188.3</td>
<td>148.0</td>
<td>190.5</td>
</tr>
<tr>
<td>Long-term debt, other than revolving credit facility</td>
<td>2,904.3</td>
<td>2.4</td>
<td>579.9</td>
<td>905.0</td>
<td>1,417.0</td>
</tr>
<tr>
<td>Total contractual cash obligations(c)</td>
<td>$4,040.6</td>
<td>$353.4</td>
<td>$915.7</td>
<td>$1,120.1</td>
<td>$1,651.4</td>
</tr>
</tbody>
</table>

(a) Contingent future licensing payments will be made if certain events take place, such as the launch of a specific test, the transfer of certain technology, and when specified revenue milestones are met.

(b) As announced by the Company on January 2, 2014, holders of the zero-coupon subordinated notes may choose to convert their notes during the first quarter of 2014 subject to terms as defined in the note agreement. See “Note 11 to Consolidated Financial Statements” and “Credit Ratings” above for further information regarding the Company’s zero-coupon subordinated notes.

(c) The table does not include obligations under the Company’s pension and postretirement benefit plans, which are included in “Note 16 to Consolidated Financial Statements.” Benefits under the Company’s postretirement medical plan are made when claims are submitted for payment, the timing of which is not practicable to estimate.

Off-Balance Sheet Arrangements
The Company does not have transactions or relationships with “special purpose” entities, and the Company does not have any off balance sheet financing other than normal operating leases.

Other Commercial Commitments
As of December 31, 2013, the Company provided letters of credit aggregating approximately $42.5, primarily in connection with certain insurance programs. Letters of credit provided by the Company are secured by the Company’s Revolving Credit Facility and are renewed annually, around mid-year.

On October 14, 2011, the Company issued notice to a noncontrolling interest holder in its Other segment of its intent to purchase the holder’s partnership units in accordance with the terms of the joint venture’s partnership agreement. On November 28, 2011, this purchase was completed for a total purchase price of CN$151.7 as outlined in the partnership agreement (CN$147.8 plus certain adjustments relating to cash distribution hold backs made to finance recent business acquisitions and capital expenditures). The purchase of these additional partnership units brings the Company’s percentage interest owned to 98.2%.
The contractual value of the remaining noncontrolling interest put totals $19.4 at December 31, 2013. At December 31, 2013 and 2012, $19.4 and $20.7, respectively, have been classified as mezzanine equity in the Company’s consolidated balance sheet.

Based on current and projected levels of operations, coupled with availability under its Revolving Credit Facility, the Company believes it has sufficient liquidity to meet both its anticipated short-term and long-term cash needs; however, the Company continually reassesses its liquidity position in light of market conditions and other relevant factors.

New Accounting Pronouncements
In March 2013, the FASB issued a new accounting standard on foreign currency matters that clarifies the guidance of a parent company’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity.

Under this new standard, a parent company that ceases to have a controlling financial interest in a foreign subsidiary or group of assets within a foreign entity shall release any related cumulative translation adjustment into net income only if a sale or transfer results in complete or substantially complete liquidation of the foreign entity. This standard shall be applied prospectively and will become effective for the Company on January 1, 2014. The Company expects that the adoption of this standard will not have a material effect on its consolidated financial statements.

Critical Accounting Policies
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. While the Company believes these estimates are reasonable and consistent, they are by their very nature, estimates of amounts that will depend on future events. Accordingly, actual results could differ from these estimates. The Company’s Audit Committee periodically reviews the Company’s significant accounting policies. The Company’s critical accounting policies arise in conjunction with the following:

- Revenue recognition and allowance for doubtful accounts;
- Pension expense;
- Accruals for self insurance reserves;
- Income taxes; and
- Goodwill and indefinite-lived assets
Revenue recognition and allowance for doubtful accounts

Revenue is recognized for services rendered when the testing process is complete and test results are reported to the ordering physician. The Company’s sales are generally billed to three types of payers – clients, patients and third parties such as managed care companies, Medicare and Medicaid. For clients, sales are recorded on a fee-for-service basis at the Company’s client list price, less any negotiated discount. Patient sales are recorded at the Company’s patient fee schedule, net of any discounts negotiated with physicians on behalf of their patients, or fees made available through patient hardship programs. The Company bills third-party payers in two ways – fee-for-service and capitated agreements. Fee-for-service third-party payers are billed at the Company’s patient fee schedule amount, and third-party revenue is recorded net of contractual discounts. These discounts are recorded at the transaction level at the time of sale based on a fee schedule that is maintained for each third-party payer. The majority of the Company’s third-party sales are recorded using an actual or contracted fee schedule at the time of sale. For the remaining third-party sales, estimated fee schedules are maintained for each payer. Adjustments to the estimated payment amounts are recorded at the time of final collection and settlement of each transaction as an adjustment to revenue. These adjustments are not material to the Company’s results of operations in any period presented. The Company periodically adjusts these estimated fee schedules based upon historical payment trends. Under capitated agreements with managed care companies, the Company recognizes revenue based on a negotiated monthly contractual rate for each member of the managed care plan regardless of the number or cost of services performed.

The Company has a formal process to estimate and review the collectibility of its receivables based on the period of time they have been outstanding. Bad debt expense is recorded within selling, general and administrative expenses as a percentage of sales considered necessary to maintain the allowance for doubtful accounts at an appropriate level. The Company’s process for determining the appropriate level of the allowance for doubtful accounts involves judgment, and considers such factors as the age of the underlying receivables, historical and projected collection experience, and other external factors that could affect the collectibility of its receivables. Accounts are written off against the allowance for doubtful accounts based on the Company’s write-off policy (e.g., when they are deemed to be uncollectible). In the determination of the appropriate level of the allowance, accounts are progressively reserved based on the historical timing of cash collections relative to their respective aging categories within the Company’s receivables. These collection and reserve processes, along with the close monitoring of the billing process, help reduce the risks of material revisions to reserve estimates resulting from adverse changes in collection or reimbursement experience.

The following table presents the percentage of the Company’s net accounts receivable outstanding by aging category at December 31, 2013 and 2012:

<table>
<thead>
<tr>
<th>Days Outstanding</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 30</td>
<td>46.4%</td>
<td>48.9%</td>
</tr>
<tr>
<td>31 – 60</td>
<td>19.3%</td>
<td>18.6%</td>
</tr>
<tr>
<td>61 – 90</td>
<td>11.5%</td>
<td>11.7%</td>
</tr>
<tr>
<td>91 – 120</td>
<td>7.1%</td>
<td>6.5%</td>
</tr>
<tr>
<td>121 – 150</td>
<td>3.4%</td>
<td>3.9%</td>
</tr>
<tr>
<td>151 – 180</td>
<td>3.8%</td>
<td>3.3%</td>
</tr>
<tr>
<td>181 – 270</td>
<td>7.3%</td>
<td>6.1%</td>
</tr>
<tr>
<td>271 – 360</td>
<td>0.9%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Over 360</td>
<td>0.3%</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

The above table excludes the percentage of net accounts receivable outstanding by aging category for the Other segment, and its other smaller foreign operations. Combined, these foreign net accounts receivable balances comprise less than 8.0% of the Company’s total net accounts receivable balances. The Company believes that including the agings for these foreign operations would not be representative of the majority of the accounts receivable by aging category for the Company. The majority of the foreign accounts receivable are due from the provincial government and are generally paid within 30-60 days of billing.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

Pension Expense
In October 2009, the Company received approval from its Board of Directors to freeze any additional service-based credits for any years of service after December 31, 2009 on the Company Plan and the PEP. Both plans have been closed to new participants. Employees participating in the Company Plan and the PEP no longer earn service-based credits, but continue to earn interest credits. In addition, effective January 1, 2010, all employees eligible for the defined contribution retirement plan (the "401K Plan") receive a minimum 3% non-elective contribution ("NEC") concurrent with each payroll period. The 401K Plan also permits discretionary contributions by the Company of 1% to 3% of pay for eligible employees based on service.

The Company Plan covers substantially all employees hired prior to December 31, 2009. The benefits to be paid under the Company Plan are based on years of credited service through December 31, 2009, interest credits and average compensation. The Company also has the PEP which covers its senior management group. Prior to 2010, the PEP provided for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan but for such limitation.

The Company's net pension cost is developed from actuarial valuations. Inherent in these valuations are key assumptions, including discount rates and expected return on plan assets, which are updated on an annual basis at the beginning of each year. The Company is required to consider current market conditions, including changes in interest rates, in making these assumptions. Changes in pension costs may occur in the future due to changes in these assumptions. The key assumptions used in accounting for the defined benefit retirement plans were a 4.80% discount rate and a 7.0% expected long-term rate of return on plan assets as of December 31, 2013.

Discount Rate
The Company evaluates several approaches toward setting the discount rate assumption that is used to value the benefit obligations of its retirement plans. At year-end, priority was given to use of the Towers Watson Bond:Link model, which simulates the purchase of investment-grade corporate bonds at current market yields with principal amounts and maturity dates closely matching the Company’s projected cash disbursements from its plans. This completed model represents the yields to maturity that the Company could theoretically settle its plan obligations at year end. The weighted-average yield on the modeled bond portfolio is then used to form the discount rate assumption used for each retirement plan. A one percentage point decrease or increase in the discount rate would have resulted in a respective increase or decrease in 2013 retirement plan expense of $2.7.

Return on Plan Assets
In establishing its expected return on plan assets assumption, the Company reviews its asset allocation and develops return assumptions based on different asset classes adjusting for plan operating expenses. Actual asset over/under performance compared to expected returns will respectively decrease/increase unrecognized loss. The change in the unrecognized loss will change amortization cost in upcoming periods. A one percentage point increase or decrease in the expected return on plan assets would have resulted in a corresponding change in 2013 pension expense of $2.5.

Net pension cost for 2013 was $11.0 as compared with $12.1 in 2012 and $8.6 in 2011. The decrease in pension expense was due to increases in the amount of net amortization and deferral as a result of higher discount rates. The increase in pension expense in 2012 was due to increases in the amount of net amortization and deferral as a result of lower discount rates and a 25 basis point decrease in the expected return on assets as a result of declines in asset market values in 2011. Projected pension expense for the Company Plan and the PEP is expected to decrease to $7.8 in 2014.

Further information on the Company’s defined benefit retirement plan is provided in Note 16 to the consolidated financial statements.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

Accruals for Self-insurance Reserves
Accruals for self-insurance reserves (including workers’ compensation, auto and employee medical) are determined based on a number of assumptions and factors, including historical payment trends and claims history, actuarial assumptions and current and estimated future economic conditions. These estimated liabilities are not discounted.

The Company is self-insured (up to certain limits) for professional liability claims arising in the normal course of business, generally related to the testing and reporting of laboratory test results. The Company maintains excess insurance which limits the Company’s maximum exposure on individual claims. The Company estimates a liability that represents the ultimate exposure for aggregate losses below those limits. The liability is discounted and is based on actuarial assumptions and factors for known and incurred but not reported claims, including the frequency and payment trends of historical claims.

If actual trends differ from these estimates, the financial results could be impacted. Historical trends have not differed materially from these estimates.

Income Taxes
The Company accounts for income taxes utilizing the asset and liability method. Under this method deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company does not recognize a tax benefit, unless the Company concludes that it is more likely than not that the benefit will be sustained on audit by the taxing authority based solely on the technical merits of the associated tax position. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that the Company believes is greater than 50% likely to be realized. The Company records interest and penalties in income tax expense.

Goodwill and Indefinite-Lived Assets
The Company assesses goodwill and indefinite lived intangibles for impairment at least annually and more frequently if triggering events occur. The timing of the Company’s annual impairment testing is the end of the fiscal year. In accordance with the Financial Accounting Standards Board (“FASB”) updates to their authoritative guidance regarding goodwill and indefinite-lived intangible asset impairment testing, an entity is allowed to first assess qualitative factors as a basis for determining whether it is necessary to perform quantitative impairment testing. If an entity determines that it is not more likely than not that the estimated fair value of an asset is less than its carrying value, then no further testing is required. Otherwise, impairment testing must be performed in accordance with the original accounting standards. The updated FASB guidance also allows an entity to bypass the qualitative assessment for any reporting unit in its goodwill assessment and proceed directly to performing the first step of the two-step assessment. Similarly, a company can proceed directly to a quantitative assessment in the case of impairment testing for indefinite-lived intangible assets as well. In 2013 and 2012, the Company elected to bypass the purely qualitative assessments for its goodwill and indefinite-lived intangible assets and proceed to quantitative assessments utilizing methodologies as described in the following paragraphs.

Step One of the goodwill impairment test includes the estimation of the fair value of each reporting unit as compared to the book value of the reporting unit. The Company uses a market value approach for determining fair value and utilizes a number of factors such as publicly available information regarding the market capitalization of the Company as well as operating results, business plans, and present value techniques. If Step One indicates potential impairment, the second step is performed to measure the amount of the impairment.

The Company has indefinite-lived assets consisting of acquired Canadian licenses. When a quantitative analysis is considered necessary for indefinite-lived intangible assets, the Company utilizes an income approach to determine the fair value. It then compares the carrying value of the indefinite-lived asset to its fair value. Impairment losses are recorded to the extent that the carrying value of the indefinite-lived intangible asset exceeds its fair value.

There are inherent uncertainties related to the factors described above and judgment related to our impairment assessments of goodwill and indefinite-lived intangibles. The assumptions underlying the impairment analyses may change in such a manner that impairment in value may occur in the future. Any such impairment will be recognized in the period in which it becomes known.
Forward-Looking Statements
The Company has made in this report, and from time to time may otherwise make in its public filings, press releases and discussions by Company management, forward-looking statements concerning the Company’s operations, performance and financial condition, as well as its strategic objectives. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein and in the Company’s other public filings, press releases and discussions with Company management, including:

1. changes in federal, state, local and third-party payer regulations or policies or other future reforms in the health care system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (Health Insurance Exchanges), new public insurance programs or a single-payer system, affecting governmental and third-party coverage or reimbursement for clinical laboratory testing;
2. significant monetary damages, fines, penalties, assessments, refunds, repayments, and/or exclusion from Medicare and Medicaid programs resulting from investigations, audits, regulatory examinations, information requests, and other inquiries by the government;
3. loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of, the law or regulations of the Clinical Laboratory Improvement Act of 1967, and the Clinical Laboratory Improvement Amendments of 1988, or those of Medicare, Medicaid, the False Claims Act or other federal, state or local agencies;
4. penalties or loss of license arising from the failure to comply with the Federal Occupational Safety and Health Administration requirements and the Needlestick Safety and Prevention Act;
5. increased costs, denial of claims and/or significant penalties arising from the failure to comply with HIPAA, including changes to federal and state privacy and security obligations and changes to HITECH and any subsequent amendments;
6. subsequent costs due to damage to the Company’s reputation and significant litigation exposure arising from the failure to maintain the security of business information or systems or protect against cyber security attacks;
7. negative impact on the Company’s reimbursement, cash collections, days sales outstanding and profitability arising from the failure of the Company, third-party payers or physicians to comply with the ICD-10-CM Code Set by the compliance date of October 1, 2014;
8. increased competition, including competition from companies that do not comply with existing laws or regulations or otherwise disregard compliance standards in the industry;
9. increased price competition, competitive bidding for laboratory tests and/or changes or reductions to fee schedules;
10. changes in payer mix, including an increase in capitated reimbursement mechanisms or the impact of a shift to consumer-driven health plans and adverse changes in payer reimbursement or payer coverage policies related to specific testing procedures or categories of testing;
11. failure to obtain and retain new customers or a reduction in tests ordered or specimens submitted by existing customers;
12. failure to retain or attract managed care business as a result of changes in business models, including new risk based or network approaches, or other changes in strategy or business models by managed care companies;
13. failure to effectively integrate and/or manage newly acquired businesses and the cost related to such integrations;
14. adverse results in litigation matters;
15. inability to attract and retain experienced and qualified personnel;
Management’s Discussion and Analysis of Financial Condition and Results of Operations (in millions)

16. business interruption, increased costs, and other adverse effects on the Company’s operations due to the unionization of employees, union strikes, work stoppages, or general labor unrest;
17. failure to maintain the Company’s days sales outstanding and/or bad debt expense levels;
18. decrease in the Company’s credit ratings by Standard & Poor’s and/or Moody’s;
19. discontinuation or recalls of existing testing products;
20. failure to develop or acquire licenses for new or improved technologies, or if customers use new technologies to perform their own tests;
21. substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;
22. failure to identify and successfully close and integrate strategic acquisition targets;
23. changes in government regulations or policies, including regulations and policies of the Food and Drug Administration, affecting the approval, availability of, and the selling and marketing of diagnostic tests;
24. inability to obtain and maintain adequate patent and other proprietary rights for protection of the Company’s products and services and successfully enforce the Company’s proprietary rights;
25. the scope, validity and enforceability of patents and other proprietary rights held by third parties which might have an impact on the Company’s ability to develop, perform, or market the Company’s tests or operate its business;
26. failure in the Company’s information technology systems resulting in an increase in testing turnaround time or billing processes or the failure to meet future regulatory or customer information technology, data security and connectivity requirements;
27. failure to meet required financial reporting deadlines arising from a failure of the Company’s financial information systems;
28. failure of the Company’s disaster recovery plans to provide adequate protection against the interruption of business and/or to permit the recovery of business operations;
29. business interruption or other impact on the business due to adverse weather (including hurricanes), fires and/or other natural disasters, terrorism or other criminal acts, and/or widespread outbreak of influenza or other pandemic illness;
30. liabilities that result from the inability to comply with corporate governance requirements;
31. impact on the Company’s testing volumes, cash collections and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets;
32. changes in reimbursement by foreign governments and foreign currency fluctuations; and
33. expenses and risks associated with international operations, including but not limited to compliance with the Foreign Corrupt Practices Act, the U.K. Bribery Act, as well as laws and regulations that differ from those of the U.S., and economic, political, legal and other operational risks associated with foreign markets.
Quantitative and Qualitative Disclosure About Market Risk

The Company addresses its exposure to market risks, principally the market risk associated with changes in interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as interest rate swap agreements. Although, as set forth below, the Company’s zero-coupon subordinated notes contain features that are considered to be embedded derivative instruments, the Company does not hold or issue derivative financial instruments for trading purposes. The Company does not believe that its exposure to market risk is material to the Company’s financial position or results of operations.

During the third quarter of 2013, the Company entered into two fixed-to-variable interest rate swap agreements for the 4.625% senior notes due 2020 with an aggregate notional amount of $600.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company’s long term debt.

The Company’s zero-coupon subordinated notes contain the following two features that are considered to be embedded derivative instruments under authoritative guidance in connection with accounting for derivative instruments and hedging activities:

1) The Company will pay contingent cash interest on the zero-coupon subordinated notes after September 11, 2006, if the average market price of the notes equals 120% or more of the sum of the issue price, accrued original issue discount and contingent additional principal, if any, for a specified measurement period.

2) Holders may surrender zero-coupon subordinated notes for conversion during any period in which the rating assigned to the zero-coupon subordinated notes by Standard & Poor’s Ratings Services is BB- or lower.

Borrowings under the Company’s revolving credit facility are subject to variable interest rates, unless fixed through interest rate swaps or other agreements.

The Company’s Ontario, Canada consolidated joint venture operates in Canada and, accordingly, the earnings and cash flows generated from the Ontario operations are subject to foreign currency exchange risk.

The Company’s wholly-owned subsidiary, Clearstone Central Laboratories, has operations in China and Singapore, and, accordingly the earnings and cash flows generated from these operations are subject to foreign currency risk.

The Company’s wholly-owned subsidiary, Orchid, has operations in the United Kingdom and, accordingly the earnings and cash flows generated from Orchid’s United Kingdom operation are subject to foreign currency risk.

The Alberta, Canada joint venture partnership operates in Canada and remits the Company’s share of partnership income in Canadian dollars. Accordingly, the cash flow received from this affiliate is subject to foreign currency exchange risk.
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).

The internal control over financial reporting at the Company was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America;
- provide reasonable assurance that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

The Company’s management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2013. Management based this assessment on criteria for effective internal control over financial reporting described in “Internal Control–Integrated Framework 1992” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, the Company’s management determined that, as of December 31, 2013, the Company maintained effective internal control over financial reporting. Management reviewed the results of its assessment with the Audit Committee of the Company’s Board of Directors.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, who audited and reported on the consolidated financial statements of the Company included in this annual report, also audited the effectiveness of the Company’s internal control over financial reporting as of December 31, 2013 as stated in its report, which is included herein immediately preceding the Company’s audited financial statements.
To the Board of Directors and Shareholders of Laboratory Corporation of America Holdings:

In our opinion, the consolidated balance sheets and related consolidated statements of operations, comprehensive earnings, changes in shareholders’ equity and cash flows present fairly, in all material respects, the financial position of Laboratory Corporation of America Holdings and its subsidiaries at December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013 in conformity with accounting principles generally accepted in the United States of America. In our opinion, the Company’s management is responsible for these statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the Report of Management on Internal Control Over Financial Reporting. Our responsibility is to express opinions on these statements, and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PricewaterhouseCoopers LLP
Charlotte, North Carolina
February 25, 2014
### Consolidated Balance Sheets

<table>
<thead>
<tr>
<th>(In Millions)</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$404.0</td>
<td>$466.8</td>
</tr>
<tr>
<td>Accounts receivable, net of allowance for doubtful accounts</td>
<td>784.7</td>
<td>718.5</td>
</tr>
<tr>
<td>at December 31, 2013 and 2012, respectively</td>
<td>121.0</td>
<td></td>
</tr>
<tr>
<td>Supplies inventories</td>
<td>136.5</td>
<td>121.0</td>
</tr>
<tr>
<td>Prepaid expenses and other</td>
<td>106.9</td>
<td>74.6</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td></td>
<td>10.9</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>1,432.1</td>
<td>1,391.8</td>
</tr>
<tr>
<td>Property, plant and equipment, net</td>
<td>707.4</td>
<td>630.8</td>
</tr>
<tr>
<td>Goodwill, net</td>
<td>3,022.8</td>
<td>2,901.7</td>
</tr>
<tr>
<td>Intangible assets, net</td>
<td>1,572.0</td>
<td>1,667.7</td>
</tr>
<tr>
<td>Joint venture partnerships and equity method investments</td>
<td>88.5</td>
<td>78.1</td>
</tr>
<tr>
<td>Other assets, net</td>
<td>143.1</td>
<td>124.9</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$6,965.9</td>
<td>$6,795.0</td>
</tr>
</tbody>
</table>

| **LIABILITIES AND SHAREHOLDERS’ EQUITY** |          |          |
| Current liabilities:       |          |          |
| Accounts payable           | $304.5   | $236.9   |
| Accrued expenses and other | 310.0    | 311.6    |
| Deferred income taxes      | 9.9      | –        |
| Short-term borrowings and current portion of long-term debt | 111.3    | 480.0    |
| **Total current liabilities** | 735.7    | 1,028.5  |
| Long-term debt, less current portion | 2,889.1  | 2,175.0  |
| Deferred income taxes and other tax liabilities | 563.9    | 546.0    |
| Other liabilities          | 266.5    | 307.4    |
| **Total liabilities**      | 4,455.2  | 4,056.9  |

| Commitments and contingent liabilities | 19.4 | 20.7 |
| Noncontrolling interest            |      |      |

| Shareholders’ equity |          |          |
| Common stock, 85.7 and 93.5 shares outstanding at December 31, 2013 and 2012, respectively | 10.5 | 11.3 |
| Additional paid-in capital       | –      | –       |
| Retained earnings                | 3,373.5| 3,588.5 |
| Less common stock held in treasury | (958.9)| (951.8) |
| Accumulated other comprehensive income | 66.2   | 69.4    |
| **Total shareholders’ equity**   | 2,491.3| 2,717.4 |
| **Total liabilities and shareholders’ equity** | $6,965.9 | $6,795.0 |

*The accompanying notes are an integral part of these consolidated financial statements.*
## Consolidated Statements of Operations

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$5,808.3</td>
<td>$5,671.4</td>
<td>$5,542.3</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>3,585.1</td>
<td>3,421.7</td>
<td>3,267.6</td>
</tr>
<tr>
<td>Gross profit</td>
<td>2,223.2</td>
<td>2,249.7</td>
<td>2,274.7</td>
</tr>
<tr>
<td>Selling, general and administrative expenses</td>
<td>1,128.8</td>
<td>1,114.6</td>
<td>1,159.6</td>
</tr>
<tr>
<td>Amortization of intangibles and other assets</td>
<td>81.7</td>
<td>86.3</td>
<td>85.8</td>
</tr>
<tr>
<td>Restructuring and other special charges</td>
<td>21.8</td>
<td>25.3</td>
<td>80.9</td>
</tr>
<tr>
<td>Operating income</td>
<td>990.9</td>
<td>1,023.5</td>
<td>948.4</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(96.5)</td>
<td>(94.5)</td>
<td>(87.5)</td>
</tr>
<tr>
<td>Equity method income, net</td>
<td>16.9</td>
<td>21.4</td>
<td>9.5</td>
</tr>
<tr>
<td>Investment income</td>
<td>2.2</td>
<td>1.0</td>
<td>1.3</td>
</tr>
<tr>
<td>Other, net</td>
<td>2.1</td>
<td>(7.2)</td>
<td>(5.6)</td>
</tr>
<tr>
<td>Earnings before income taxes</td>
<td>915.6</td>
<td>944.2</td>
<td>866.1</td>
</tr>
<tr>
<td>Provision for income taxes</td>
<td>340.2</td>
<td>359.4</td>
<td>333.0</td>
</tr>
<tr>
<td>Net earnings</td>
<td>575.4</td>
<td>584.8</td>
<td>533.1</td>
</tr>
<tr>
<td>Less: Net earnings attributable to the noncontrolling interest</td>
<td>(1.6)</td>
<td>(1.7)</td>
<td>(13.4)</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>$573.8</td>
<td>$583.1</td>
<td>$519.7</td>
</tr>
<tr>
<td>Basic earnings per common share</td>
<td>$ 6.36</td>
<td>$ 6.09</td>
<td>$ 5.20</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>$ 6.25</td>
<td>$ 5.99</td>
<td>$ 5.11</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.

## Consolidated Statements of Comprehensive Earnings

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net earnings</td>
<td>$575.4</td>
<td>$584.8</td>
<td>$533.1</td>
</tr>
<tr>
<td>Foreign currency translation adjustments</td>
<td>(63.2)</td>
<td>31.3</td>
<td>(13.2)</td>
</tr>
<tr>
<td>Interest rate swap adjustments</td>
<td>–</td>
<td>–</td>
<td>2.4</td>
</tr>
<tr>
<td>Net benefit plan adjustments</td>
<td>42.1</td>
<td>7.3</td>
<td>(57.5)</td>
</tr>
<tr>
<td>Investment adjustments</td>
<td>16.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other comprehensive earnings (loss) before tax</td>
<td>(4.7)</td>
<td>38.6</td>
<td>(68.3)</td>
</tr>
<tr>
<td>Provision for income tax related to items of comprehensive earnings</td>
<td>1.5</td>
<td>(14.7)</td>
<td>25.3</td>
</tr>
<tr>
<td>Other comprehensive earnings (loss), net of tax</td>
<td>(3.2)</td>
<td>23.9</td>
<td>(43.0)</td>
</tr>
<tr>
<td>Comprehensive earnings</td>
<td>572.2</td>
<td>608.7</td>
<td>490.1</td>
</tr>
<tr>
<td>Less: Net earnings attributable to the noncontrolling interest</td>
<td>(1.6)</td>
<td>(1.7)</td>
<td>(13.4)</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>$570.6</td>
<td>$607.0</td>
<td>$476.7</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
## Consolidated Statements of Changes in Shareholders’ Equity

<table>
<thead>
<tr>
<th>(In Millions)</th>
<th>Common Stock</th>
<th>Additional Paid-in Capital</th>
<th>Retained Earnings</th>
<th>Treasury Stock</th>
<th>Accumulated Other Comprehensive Income (Loss)</th>
<th>Total Shareholders’ Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BALANCE AT DECEMBER 31, 2010</strong></td>
<td>$12.2</td>
<td>$53.9</td>
<td>$3,246.6</td>
<td>$(934.9)</td>
<td>$88.5</td>
<td>$2,466.3</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>–</td>
<td>–</td>
<td>519.7</td>
<td>–</td>
<td>–</td>
<td>519.7</td>
</tr>
<tr>
<td>Other comprehensive earnings, net of tax</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(43.0)</td>
<td>(43.0)</td>
</tr>
<tr>
<td>Issuance of common stock under employee stock plans</td>
<td>0.1</td>
<td>117.9</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>118.0</td>
</tr>
<tr>
<td>Surrender of restricted stock and performance share awards</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(6.0)</td>
<td>–</td>
<td>(6.0)</td>
</tr>
<tr>
<td>Conversion of zero-coupon convertible debt</td>
<td>0.1</td>
<td>36.1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>36.2</td>
</tr>
<tr>
<td>Stock compensation</td>
<td>–</td>
<td>48.9</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>48.9</td>
</tr>
<tr>
<td>Purchase of noncontrolling interest</td>
<td>–</td>
<td>(3.7)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(3.7)</td>
</tr>
<tr>
<td>Income tax benefit from stock options exercised</td>
<td>–</td>
<td>11.0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>11.0</td>
</tr>
<tr>
<td>Purchase of common stock</td>
<td>(0.7)</td>
<td>(264.1)</td>
<td>(379.1)</td>
<td>–</td>
<td>–</td>
<td>(643.9)</td>
</tr>
<tr>
<td><strong>BALANCE AT DECEMBER 31, 2011</strong></td>
<td>$11.7</td>
<td>$–</td>
<td>$3,387.2</td>
<td>$(940.9)</td>
<td>$45.5</td>
<td>$2,503.5</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>–</td>
<td>–</td>
<td>583.1</td>
<td>–</td>
<td>–</td>
<td>583.1</td>
</tr>
<tr>
<td>Other comprehensive earnings, net of tax</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>23.9</td>
<td>23.9</td>
</tr>
<tr>
<td>Issuance of common stock under employee stock plans</td>
<td>0.1</td>
<td>85.1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>85.2</td>
</tr>
<tr>
<td>Surrender of restricted stock and performance share awards</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(10.9)</td>
<td>–</td>
<td>(10.9)</td>
</tr>
<tr>
<td>Conversion of zero-coupon convertible debt</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stock compensation</td>
<td>–</td>
<td>40.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>40.7</td>
</tr>
<tr>
<td>Purchase of noncontrolling interest</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Income tax benefit from stock options exercised</td>
<td>–</td>
<td>8.4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>8.4</td>
</tr>
<tr>
<td>Purchase of common stock</td>
<td>(0.7)</td>
<td>(134.2)</td>
<td>(381.8)</td>
<td>–</td>
<td>–</td>
<td>(516.5)</td>
</tr>
<tr>
<td><strong>BALANCE AT DECEMBER 31, 2012</strong></td>
<td>$11.3</td>
<td>$–</td>
<td>$3,588.5</td>
<td>$(951.8)</td>
<td>$69.4</td>
<td>$2,717.4</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>–</td>
<td>–</td>
<td>573.8</td>
<td>–</td>
<td>–</td>
<td>573.8</td>
</tr>
<tr>
<td>Other comprehensive earnings, net of tax</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(3.2)</td>
<td>(3.2)</td>
</tr>
<tr>
<td>Issuance of common stock under employee stock plans</td>
<td>0.2</td>
<td>173.8</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>174.0</td>
</tr>
<tr>
<td>Surrender of restricted stock and performance share awards</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(7.1)</td>
<td>–</td>
<td>(7.1)</td>
</tr>
<tr>
<td>Conversion of zero-coupon convertible debt</td>
<td>–</td>
<td>4.1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4.1</td>
</tr>
<tr>
<td>Stock compensation</td>
<td>–</td>
<td>37.3</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>37.3</td>
</tr>
<tr>
<td>Income tax benefit from stock options exercised</td>
<td>–</td>
<td>10.6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>10.6</td>
</tr>
<tr>
<td>Purchase of common stock</td>
<td>(1.0)</td>
<td>(225.8)</td>
<td>(788.8)</td>
<td>–</td>
<td>–</td>
<td>(1,015.6)</td>
</tr>
<tr>
<td><strong>BALANCE AT DECEMBER 31, 2013</strong></td>
<td>$10.5</td>
<td>$–</td>
<td>$3,373.5</td>
<td>$(958.9)</td>
<td>$66.2</td>
<td>$2,491.3</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
### Consolidated Statements of Cash Flows

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net earnings</td>
<td>$575.4</td>
<td>$584.8</td>
<td>$533.1</td>
</tr>
<tr>
<td>Adjustments to reconcile net earnings to net cash provided by operating activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>230.1</td>
<td>229.8</td>
<td>231.4</td>
</tr>
<tr>
<td>Stock compensation</td>
<td>37.3</td>
<td>40.7</td>
<td>48.9</td>
</tr>
<tr>
<td>(Gain)/loss on sale of assets</td>
<td>(3.9)</td>
<td>5.5</td>
<td>7.2</td>
</tr>
<tr>
<td>Accrued interest on zero-coupon subordinated notes</td>
<td>2.3</td>
<td>2.7</td>
<td>3.9</td>
</tr>
<tr>
<td>Cumulative earnings less than (in excess of) distributions from equity method investments</td>
<td>(4.2)</td>
<td>(0.4)</td>
<td>1.4</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>56.2</td>
<td>53.3</td>
<td>2.2</td>
</tr>
<tr>
<td>Change in assets and liabilities (net of effects of acquisitions):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Increase) decrease in accounts receivable (net)</td>
<td>(67.5)</td>
<td>0.6</td>
<td>(37.1)</td>
</tr>
<tr>
<td>Increase in inventories</td>
<td>(15.3)</td>
<td>(6.3)</td>
<td>(6.1)</td>
</tr>
<tr>
<td>(Increase) decrease in prepaid expenses and other</td>
<td>(32.3)</td>
<td>7.1</td>
<td>9.8</td>
</tr>
<tr>
<td>Increase (decrease) in accounts payable</td>
<td>60.8</td>
<td>(30.0)</td>
<td>(8.7)</td>
</tr>
<tr>
<td>Increase (decrease) in accrued expenses and other</td>
<td>(20.2)</td>
<td>(46.4)</td>
<td>69.6</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>818.7</td>
<td>841.4</td>
<td>855.6</td>
</tr>
<tr>
<td><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>(202.2)</td>
<td>(173.8)</td>
<td>(145.7)</td>
</tr>
<tr>
<td>Proceeds from sale of assets</td>
<td>1.1</td>
<td>3.2</td>
<td>3.7</td>
</tr>
<tr>
<td>Proceeds from sale of investments</td>
<td>7.5</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Acquisition of licensing technology</td>
<td>–</td>
<td>(2.5)</td>
<td>–</td>
</tr>
<tr>
<td>Investments in equity affiliates</td>
<td>(6.5)</td>
<td>(26.0)</td>
<td>–</td>
</tr>
<tr>
<td>Acquisition of businesses, net of cash acquired</td>
<td>(159.5)</td>
<td>(335.1)</td>
<td>(138.3)</td>
</tr>
<tr>
<td>Net cash used for investing activities</td>
<td>(359.6)</td>
<td>(534.2)</td>
<td>(280.3)</td>
</tr>
<tr>
<td><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from senior notes offerings</td>
<td>700.0</td>
<td>1,000.0</td>
<td>–</td>
</tr>
<tr>
<td>Proceeds from revolving credit facilities</td>
<td>412.0</td>
<td>305.0</td>
<td>880.0</td>
</tr>
<tr>
<td>Payments on revolving credit facilities</td>
<td>(412.0)</td>
<td>(865.0)</td>
<td>(320.0)</td>
</tr>
<tr>
<td>Principal payments on term loan</td>
<td>–</td>
<td>–</td>
<td>(375.0)</td>
</tr>
<tr>
<td>Payments on zero-coupon subordinated notes</td>
<td>(21.5)</td>
<td>(8.2)</td>
<td>(155.1)</td>
</tr>
<tr>
<td>Payments on long-term debt</td>
<td>(350.0)</td>
<td>–</td>
<td>(0.9)</td>
</tr>
<tr>
<td>Payment of debt issuance costs</td>
<td>(9.3)</td>
<td>(8.9)</td>
<td>(3.6)</td>
</tr>
<tr>
<td>Payments on long-term lease obligations</td>
<td>(0.4)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cash paid to acquire an interest in a consolidated subsidiary</td>
<td>–</td>
<td>–</td>
<td>(147.9)</td>
</tr>
<tr>
<td>Noncontrolling interest distributions</td>
<td>(0.9)</td>
<td>(1.2)</td>
<td>(7.4)</td>
</tr>
<tr>
<td>Deferred payments on acquisitions</td>
<td>(5.6)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Excess tax benefits from stock based compensation</td>
<td>11.0</td>
<td>8.2</td>
<td>10.4</td>
</tr>
<tr>
<td>Net proceeds from issuance of stock to employees</td>
<td>174.0</td>
<td>85.8</td>
<td>118.4</td>
</tr>
<tr>
<td>Purchase of common stock</td>
<td>(1,015.6)</td>
<td>(516.5)</td>
<td>(643.9)</td>
</tr>
<tr>
<td>Net cash used for financing activities</td>
<td>(518.3)</td>
<td>(0.8)</td>
<td>(645.0)</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash and cash equivalents</td>
<td>(3.6)</td>
<td>1.1</td>
<td>(1.7)</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents</td>
<td>(62.8)</td>
<td>307.5</td>
<td>(71.4)</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of period</td>
<td>466.8</td>
<td>159.3</td>
<td>230.7</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of period</td>
<td>$404.0</td>
<td>$466.8</td>
<td>$159.3</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
Notes to Consolidated Financial Statements
(Dollars and shares in millions, except per share data)

1. Summary of Significant Accounting Policies

Basis of Financial Statement Presentation
Laboratory Corporation of America Holdings with its subsidiaries (the “Company”) is the second largest independent clinical laboratory company in the U.S. based on 2013 net revenues. Through a national network of laboratories, the Company offers a broad range of testing services used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed specialty and niche operations based on certain types of specialized testing capabilities and client requirements, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical research trials.

Since its founding in 1971, the Company has grown into a network of 44 primary laboratories and over 1,700 patient service centers along with a network of branches and STAT laboratories. With over 34,000 employees, the Company processes tests on approximately 490,000 patient specimens daily and provides clinical laboratory testing services to clients throughout the United States and other countries including Mexico, the Bahamas, Belgium, Germany, Italy, Spain, the United Kingdom, China, Singapore, Japan, South Korea, and three provinces in Canada. The Company operates within two reportable segments based on the way the Company manages its business.

The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20% and no representation on the investee’s board of directors) are accounted for using the cost method. All significant inter-company transactions and accounts have been eliminated. The Company does not have any variable interest entities or special purpose entities whose financial results are not included in the consolidated financial statements.

The financial statements of the Company’s foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the year. Resulting translation adjustments are included in “Accumulated other comprehensive income.”

Revenue Recognition
Sales are recognized on the accrual basis at the time test results are reported, which approximates when services are provided. Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services under third-party payer programs are included in sales net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated program payment amounts. Adjustments to the estimated payment amounts based on final settlement with the programs are recorded upon settlement as an adjustment to revenue. In 2013, 2012 and 2011, approximately 16.0%, 17.6% and 19.0%, respectively, of the Company’s revenues were derived directly from the Medicare and Medicaid programs. The Company has capitated agreements with certain managed care customers and recognizes related revenue based on a pre-determined monthly contractual rate for each member of the managed care plan regardless of the number or cost of services provided by the Company. In 2013, 2012 and 2011, approximately 3.2%, 3.0% and 2.9%, respectively, of the Company’s revenues were derived from such capitated agreements.

The Company’s net sales are comprised of the following:

<table>
<thead>
<tr>
<th>Year Ended December 31</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$5,808.3</td>
<td>$5,671.4</td>
<td>$5,542.3</td>
</tr>
<tr>
<td>Clinical diagnostics laboratory:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core Testing</td>
<td>$3,445.1</td>
<td>$3,246.6</td>
<td>$3,143.9</td>
</tr>
<tr>
<td>Genomic and Esoteric Testing</td>
<td>2,020.1</td>
<td>2,089.8</td>
<td>2,089.0</td>
</tr>
<tr>
<td>Other</td>
<td>343.1</td>
<td>335.0</td>
<td>309.4</td>
</tr>
<tr>
<td>Total</td>
<td>$5,808.3</td>
<td>$5,671.4</td>
<td>$5,542.3</td>
</tr>
</tbody>
</table>

Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Significant estimates include the allowances for doubtful accounts, deferred tax assets, fair values and amortization lives for intangible assets, and accruals for self-insurance reserves and pensions. The allowance for doubtful accounts is determined based on historical collections trends, the aging of accounts, current economic conditions and regulatory changes. Actual results could differ from those estimates.
Notes to Consolidated Financial Statements

Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

The Company maintains cash and cash equivalents with various major financial institutions. The total cash balances on deposit that exceeded the balances insured by the F.D.I.C., were approximately $52.8 at December 31, 2013. Cash equivalents at December 31, 2013, totaled $367.5, which includes amounts invested in money market funds, time deposits, municipal, treasury and government funds.

Substantially all of the Company’s accounts receivable are with companies in the health care industry and individuals. However, concentrations of credit risk are limited due to the number of the Company’s clients as well as their dispersion across many different geographic regions.

While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation. Accounts receivable balances (gross) from Medicare and Medicaid were $128.6 and $121.1 at December 31, 2013 and 2012, respectively.

For the Company’s subsidiary operations in Ontario, Canada, the Ministry of Health determines who can establish a licensed community medical laboratory and caps the amount that each of these licensed laboratories can bill the government sponsored healthcare plan. The Ontario government-sponsored healthcare plan covers the cost of clinical laboratory testing performed by the licensed laboratories. The provincial government discounts the annual testing volumes based on certain utilization discounts and establishes an annual maximum it will pay for all community laboratory tests. The agreed-upon reimbursement rates are subject to Ministry of Health review at the end of the year and can be adjusted (at the government’s discretion) based upon the actual volume and mix of test work performed by the licensed providers in the province during the year. The accounts receivable balances from the Ontario government sponsored healthcare plan was $33.2 and $26.7 at December 31, 2013 and 2012, respectively.

The portion of the Company’s accounts receivable due from patients comprises the largest portion of credit risk. At December 31, 2013 and 2012, receivables due from patients represent approximately 27.8% and 28.3% of the Company’s consolidated gross accounts receivable. The Company applies assumptions and judgments including historical collection experience for assessing collectibility and determining allowances for doubtful accounts for accounts receivable from patients.

Earnings per Share
Basic earnings per share is computed by dividing net earnings attributable to Laboratory Corporation of America Holdings by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Company’s outstanding stock options, restricted stock awards, performance share awards, and shares issuable upon conversion of zero-coupon subordinated notes.

The following represents a reconciliation of basic earnings per share to diluted earnings per share:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th></th>
<th>2012</th>
<th></th>
<th>2011</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Income</td>
<td>Shares</td>
<td>Per Share Amount</td>
<td>Income</td>
<td>Shares</td>
<td>Per Share Amount</td>
</tr>
<tr>
<td>Basic earnings per share</td>
<td>$573.8</td>
<td>90.2</td>
<td>$6.36</td>
<td>$583.1</td>
<td>95.7</td>
<td>$6.09</td>
</tr>
<tr>
<td>Stock options</td>
<td>–</td>
<td>1.1</td>
<td>–</td>
<td>0.8</td>
<td>–</td>
<td>0.9</td>
</tr>
<tr>
<td>Restricted stock awards and other</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.3</td>
<td>–</td>
<td>0.3</td>
</tr>
<tr>
<td>Effect of convertible debt, net of tax</td>
<td>–</td>
<td>0.5</td>
<td>–</td>
<td>0.6</td>
<td>–</td>
<td>0.6</td>
</tr>
<tr>
<td>Diluted earnings per share</td>
<td>$573.8</td>
<td>91.8</td>
<td>$6.25</td>
<td>$583.1</td>
<td>97.4</td>
<td>$5.99</td>
</tr>
</tbody>
</table>

The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock options</td>
<td>0.1</td>
<td>2.4</td>
<td>1.3</td>
</tr>
</tbody>
</table>
Stock Compensation Plans
The Company measures stock compensation cost for all equity awards at fair value on the date of grant and recognizes compensation expense over the service period for awards expected to vest. The fair value of restricted stock awards and performance shares is determined based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. Such value is recognized as expense over the service period, net of estimated forfeitures. The estimation of equity awards that will ultimately vest requires judgment and the Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the revision. Actual results and future estimates may differ substantially from the Company’s current estimates.

See Note 14 for assumptions used in calculating compensation expense for the Company’s stock compensation plans.

Cash Equivalents
Cash and cash equivalents consist of highly liquid instruments, such as commercial paper, time deposits, and other money market instruments, which have original maturities of three months or less.

Inventories
Inventories, consisting primarily of purchased laboratory and client supplies, are stated at the lower of cost (first-in, first-out) or market.

Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The cost of properties held under capital leases is equal to the lower of the net present value of the minimum lease payments or the fair value of the leased property at the inception of the lease. Depreciation and amortization expense is computed on all classes of assets based on their estimated useful lives, as indicated below, using the straight-line method.

Leasehold improvements and assets held under capital leases are amortized over the shorter of their estimated useful lives or the term of the related leases. Expenditures for repairs and maintenance are charged to operations as incurred. Retirements, sales and other disposals of assets are recorded by removing the cost and accumulated depreciation from the related accounts with any resulting gain or loss reflected in the consolidated statements of operations.

Capitalized Software Costs
The Company capitalizes purchased software which is ready for service and capitalizes software development costs incurred on significant projects starting from the time that the preliminary project stage is completed and the Company commits to funding a project until the project is substantially complete and the software is ready for its intended use. Capitalized costs include direct material and service costs and payroll and payroll-related costs. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. Capitalized software costs are amortized using the straight-line method over the estimated useful life of the underlying system, generally five years.

Long-Lived Assets
The Company assesses goodwill and indefinite lived intangibles for impairment at least annually and more frequently if triggering events occur. The timing of the Company’s annual impairment testing is the end of the fiscal year. In accordance with the Financial Accounting Standards Board ("FASB") updates to their authoritative guidance regarding goodwill and indefinite-lived intangible asset impairment testing, an entity is allowed to first assess qualitative factors as a basis for determining whether it is necessary to perform quantitative impairment testing. If an entity determines that it is not more likely than not that the estimated fair value of an asset is less than its carrying value, then no further testing is required. Otherwise, impairment testing must be performed in accordance with the original accounting standards. The updated FASB guidance also allows an entity to bypass the qualitative assessment for any reporting unit in its goodwill assessment and proceed directly to performing the first step of the two-step assessment. Similarly, a Company can proceed directly to a quantitative assessment in the case of impairment testing for indefinite-lived intangible assets as well. In 2013 and 2012, the Company elected to bypass the purely qualitative assessments for its goodwill and indefinite-lived intangible assets and proceed to quantitative assessments utilizing methodologies as described in the following paragraphs.
Notes to Consolidated Financial Statements

Step One of the goodwill impairment test includes the estimation of the fair value of each reporting unit as compared to the book value of the reporting unit. The Company uses a market value approach for determining fair value and utilizes a number of factors such as publicly available information regarding the market capitalization of the Company as well as operating results, business plans, and present value techniques. If Step One indicates potential impairment, the second step is performed to measure the amount of the impairment.

The Company has indefinite-lived assets consisting of acquired Canadian licenses. When a quantitative analysis is considered necessary for indefinite-lived intangible assets, the Company utilizes an income approach to determine the fair value. It then compares the carrying value of the indefinite-lived asset to its fair value. Impairment losses are recorded to the extent that the carrying value of the indefinite-lived intangible asset exceeds its fair value.

There are inherent uncertainties related to the factors described above and judgment related to the Company’s impairment assessments of goodwill and indefinite-lived intangibles. The assumptions underlying the impairment analyses may change in such a manner that impairment in value may occur in the future. Any such impairment will be recognized in the period in which it becomes known.

The Company completed an annual impairment analysis of its indefinite lived assets, including goodwill, and has found no instances of impairment as of December 31, 2013 or 2012.

Long-lived assets, other than goodwill and indefinite-lived assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. Recoverability of assets to be held and used is determined by the Company at the level for which there are identifiable cash flows by comparison of the carrying amount of the assets to future undiscounted net cash flows before interest expense and income taxes expected to be generated by the assets. Impairment, if any, is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets (based on market prices in an active market or on discounted cash flows). Assets to be disposed of are reported at the lower of the carrying amount or fair value. The Company found no instances of impairment as of December 31, 2013 or 2012.

Intangible Assets
Intangible assets are amortized on a straight-line basis over the expected periods to be benefited, as set forth in the table below, such as legal life for patents and technology and contractual lives for non-compete agreements.

<table>
<thead>
<tr>
<th>Years</th>
<th>Customer relationships</th>
<th>Patents, licenses and technology</th>
<th>Non-compete agreements</th>
<th>Trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10-30</td>
<td>3-15</td>
<td>5-10</td>
<td>5-10</td>
</tr>
</tbody>
</table>

Debt Issuance Costs
The costs related to the issuance of debt are capitalized and amortized to interest expense over the terms of the related debt.

Professional Liability
The Company is self-insured (up to certain limits) for professional liability claims arising in the normal course of business, generally related to the testing and reporting of laboratory test results. The Company estimates a liability that represents the ultimate exposure for aggregate losses below those limits. The liability is discounted and is based on actuarial assumptions and factors for known and incurred but not reported claims, including the frequency and payment trends of historical claims.

Income Taxes
The Company accounts for income taxes utilizing the asset and liability method. Under this method deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the year in which the change occurs. The Company does not recognize a tax benefit unless the Company concludes that it is more likely than not that the benefit will be sustained on audit by the taxing authority based solely on the technical merits of the associated tax position. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that the Company believes is greater than 50% likely to be realized. The Company records interest and penalties in income tax expense.
Derivative Financial Instruments
Interest rate swap agreements, which have been used by the Company from time to time in the management of interest rate exposure, are accounted for at fair value. The Company’s zero-coupon subordinated notes contain two features that are considered to be embedded derivative instruments under authoritative guidance in connection with accounting for derivative instruments and hedging activities. The Company believes these embedded derivatives had no fair value at December 31, 2013 and 2012.

See Note 18 for the Company’s objectives in using derivative instruments and the effect of derivative instruments and related hedged items on the Company’s financial position, financial performance and cash flows.

Fair Value of Financial Instruments
Fair value measurements for financial assets and liabilities are determined based on the assumptions that a market participant would use in pricing an asset or liability. A three-tiered fair value hierarchy draws distinctions between market participant assumptions based on (i) observable inputs such as quoted prices in active markets (Level 1), (ii) inputs other than quoted prices in active markets that are observable either directly or indirectly (Level 2) and (iii) unobservable inputs that require the Company to use present value and other valuation techniques in the determination of fair value (Level 3).

Research and Development
The Company expenses research and development costs as incurred.

New Accounting Pronouncements
In March 2013, the FASB issued a new accounting standard on foreign currency matters that clarifies the guidance of a parent company’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. Under this new standard, a parent company that ceases to have a controlling financial interest in a foreign subsidiary or group of assets within a foreign entity shall release any related cumulative translation adjustment into net income only if a sale or transfer results in complete or substantially complete liquidation of the foreign entity. This standard shall be applied prospectively and will become effective for the Company on January 1, 2014. The Company expects that the adoption of this standard will not have a material effect on its consolidated financial statements.

2. Business Acquisitions
During the year ended December 31, 2013, the Company acquired various laboratories and related assets for approximately $159.5 in cash (net of cash acquired). These acquisitions were made primarily to extend the Company’s geographic reach in important market areas and/or enhance the Company’s scientific differentiation and esoteric testing capabilities. The purchase consideration for these acquisitions has been allocated to the estimated fair market value of the net assets acquired, including approximately $40.9 in identifiable intangible assets (primarily customer relationships and non-compete agreements) and a residual amount of goodwill of approximately $127.0. The purchase price allocations for certain of these acquisitions are preliminary and subject to adjustment based on changes in the fair value of working capital and other assets and liabilities on the effective acquisition dates and final valuation of intangible assets.
On July 31, 2012, the Company completed its acquisition of MEDTOX Scientific, Inc. ("MEDTOX"), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, for $236.4 in cash, excluding transaction fees. The MEDTOX acquisition was made to extend the Company’s specialty toxicology testing group and enhance the Company’s scientific differentiation and esoteric testing capabilities.

The MEDTOX purchase consideration has been allocated to the estimated fair market value of the net assets acquired, including approximately $78.0 in identifiable intangible assets (primarily non-tax deductible customer relationships, trade names and trademarks) with weighted-average useful lives of approximately 18 years; $33.2 in deferred tax liabilities (relating to identifiable intangible assets); and a residual amount of non-tax deductible goodwill of approximately $154.2.

During the year ended December 31, 2012, the Company also acquired various other laboratories and related assets for approximately $95.8 in cash (net of cash acquired). These acquisitions were made primarily to extend the Company’s geographic reach in important market areas and/or enhance the Company’s scientific differentiation and esoteric testing capabilities.

In April 2011, the Company and Orchid Cellmark Inc. ("Orchid") announced that they had entered into a definitive agreement and plan of merger under which the Company would acquire all of the outstanding shares of Orchid in a cash tender offer for $2.80 per share for a total purchase price to stockholders and option holders of approximately $85.4. The tender offer and the merger were subject to customary closing conditions set forth in the agreement and plan of merger, including the acquisition in the tender offer of a majority of Orchid’s fully diluted shares and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The Company received lawsuits filed by putative classes of shareholders of Orchid in New Jersey and Delaware state courts and federal court in New Jersey alleging breaches of fiduciary duty and/or other violations of state law arising out of the proposed acquisition of Orchid. Both Orchid and the Company were named in the lawsuits. The lawsuits were subsequently dismissed.

On December 8, 2011, the Company announced that it had reached an agreement with the U.S. Federal Trade Commission allowing the Company to complete its acquisition of Orchid. Under the terms of the proposed consent decree that was accepted by the FTC for public comment, the Company was required to divest certain assets of Orchid’s U.S. government paternity business following closing of the acquisition. On December 16, 2011, the Company sold those assets to DNA Diagnostics Center, a privately held provider of DNA paternity testing. The Company completed its acquisition of Orchid on December 15, 2011. It has recorded a $2.8 non-deductible loss on the divestiture of Orchid’s U.S. government paternity business in Other Income and Expense in the accompanying Consolidated Statements of Operations.

The Orchid purchase consideration has been allocated to the estimated fair market value of the net assets acquired, including approximately $28.8 in identifiable intangible assets (primarily non-tax deductible customer relationships, trade names and trademarks) with weighted-average useful lives of approximately 12 years; $9.1 in deferred tax liabilities (relating to identifiable intangible assets); net operating loss tax assets of approximately $20.4, which are expected to be realized over a period of 20 years; and a residual amount of non-tax deductible goodwill of approximately $27.4.

During the twelve months ended December 31, 2011, the Company also acquired various laboratories and related assets for approximately $51.9 in cash (net of cash acquired). These acquisitions were made primarily to extend the Company’s geographic reach in important market areas and/or enhance the Company’s scientific differentiation and esoteric testing capabilities.

On October 14, 2011, the Company issued notice to a noncontrolling interest holder in its Other segment of its intent to purchase the holder’s partnership units in accordance with the terms of the partnership agreement. On November 28, 2011, this purchase was completed for a total purchase price of $147.9 (CN$151.7) as outlined in the partnership agreement (CN$147.8 plus certain adjustments relating to cash distribution hold backs made to finance recent business acquisitions and capital expenditures). The purchase of these additional partnership units brought the Company’s percentage interest owned to 98.2%.

Contingent consideration liabilities associated with the Company’s business acquisitions are recorded at fair value based upon the estimated probability assessment of the earn-out criteria. Changes in the fair value of contingent consideration liabilities are recognized in earnings until the arrangement is settled.
3. Restructuring and Other Special Charges

During 2013, the Company recorded net restructuring charges of $21.8. The charges were comprised of $15.4 in severance and other personnel costs and $9.5 in facility-related costs primarily associated with general integration activities. These charges were offset by the reversal of previously established reserves of $0.7 in unused severance and $2.4 in unused facility-related costs.

During 2012, the Company recorded net restructuring charges of $25.3. The charges were comprised of $16.2 in severance and other personnel costs and $19.6 in facility-related costs primarily associated with the ongoing integration activities of Orchid and Integrated Genetics Division (formerly Genzyme Genetics) and costs associated with the previously announced termination of an executive vice president. These charges were offset by the reversal of previously established reserves of $6.3 in unused severance and $4.2 in unused facility related costs.

As part of the Clearstone integration, the Company also recorded a 6.9 loss on the disposal of one of its European subsidiaries in Other, net under Other income (expenses) during 2012.

During 2011, the Company recorded net restructuring charges of $44.6. Of this amount, $27.4 related to severance and other personnel costs, and $22.0 primarily related to facility-related costs associated with the ongoing integration of certain acquisitions including Genzyme Genetics and Westcliff. These charges were offset by restructuring credits of $4.8, resulting from the reversal of unused severance and facility closure liabilities. In addition, the Company recorded fixed assets impairment charges of $18.9 primarily related to equipment, computer systems and leasehold improvements in closed facilities. The Company also recorded special charges of $14.8 related to the write-off of certain assets and liabilities related to an investment made in prior years, along with a $2.6 write-off of an uncollectible receivable from a past installment sale of one of the Company’s lab operations.

4. Restructuring Reserves

The following represents the Company’s restructuring activities for the period indicated:

<table>
<thead>
<tr>
<th></th>
<th>Severance and Other Employee Costs</th>
<th>Lease and Other Facility Costs</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance as of December 31, 2012</td>
<td>$1.4</td>
<td>$26.2</td>
<td>$27.6</td>
</tr>
<tr>
<td>Restructuring charges</td>
<td>15.4</td>
<td>9.5</td>
<td>24.9</td>
</tr>
<tr>
<td>Reduction of prior restructuring accruals</td>
<td>(0.6)</td>
<td>(2.5)</td>
<td>(3.1)</td>
</tr>
<tr>
<td>Cash payments and other adjustments</td>
<td>(15.4)</td>
<td>(8.3)</td>
<td>(23.7)</td>
</tr>
<tr>
<td>Balance as of December 31, 2013</td>
<td>$0.8</td>
<td>$24.9</td>
<td>$25.7</td>
</tr>
</tbody>
</table>

The non-current portion of the restructuring liabilities is expected to be paid out over 7 years.

5. Joint Venture Partnerships and Equity Method Investments

At December 31, 2013 the Company had investments in the following unconsolidated joint venture partnerships and equity method investments:

<table>
<thead>
<tr>
<th>Locations</th>
<th>Net Investment</th>
<th>Interest Owned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Venture Partnerships:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milwaukee, Wisconsin</td>
<td>$15.5</td>
<td>50.00%</td>
</tr>
<tr>
<td>Alberta, Canada</td>
<td>58.5</td>
<td>43.37%</td>
</tr>
<tr>
<td>Florence, South Carolina</td>
<td>10.0</td>
<td>49.00%</td>
</tr>
<tr>
<td>Equity Method Investments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Various</td>
<td>4.5</td>
<td>various</td>
</tr>
</tbody>
</table>
The joint venture agreements that govern the conduct of business of these partnerships mandates unanimous agreement between partners on all major business decisions as well as providing other participating rights to each partner. The equity method investments represent the Company’s purchase of shares in clinical diagnostic companies. The investments are accounted for under the equity method of accounting as the Company does not have control of these investments. The Company has no material obligations or guarantees to, or in support of, these unconsolidated investments and their operations.

Condensed unconsolidated financial information for joint venture partnerships and equity method investments is shown in the following table.

<table>
<thead>
<tr>
<th>As of December 31:</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current assets</td>
<td>$43.4</td>
<td>$36.8</td>
</tr>
<tr>
<td>Other assets</td>
<td>40.9</td>
<td>39.9</td>
</tr>
<tr>
<td>Total assets</td>
<td>$84.3</td>
<td>$76.7</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>21.9</td>
<td>19.6</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>1.3</td>
<td>1.7</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>23.2</td>
<td>21.3</td>
</tr>
<tr>
<td>Partners’ equity</td>
<td>61.1</td>
<td>55.4</td>
</tr>
<tr>
<td>Total liabilities and partners’ equity</td>
<td>$84.3</td>
<td>$76.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>For the period January 1-December 31:</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$255.2</td>
<td>$249.0</td>
</tr>
<tr>
<td>Gross profit</td>
<td>84.1</td>
<td>86.4</td>
</tr>
<tr>
<td>Net earnings</td>
<td>37.7</td>
<td>42.2</td>
</tr>
</tbody>
</table>

The Company’s recorded investment in the Alberta joint venture partnership at December 31, 2013 includes $45.6 of value assigned to the partnership’s Canadian license (with an indefinite life and deductible for tax) to conduct diagnostic testing services in the province.

6. Accounts Receivable, Net

<table>
<thead>
<tr>
<th>December 31, 2013</th>
<th>December 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross accounts receivable</td>
<td>$983.0</td>
</tr>
<tr>
<td>Less allowance for doubtful accounts</td>
<td>(198.3)</td>
</tr>
<tr>
<td>Total</td>
<td>$784.7</td>
</tr>
</tbody>
</table>

The provision for doubtful accounts was $254.8, $246.0 and $255.1 in 2013, 2012 and 2011, respectively.

7. Property, Plant and Equipment, Net

<table>
<thead>
<tr>
<th>December 31, 2013</th>
<th>December 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Land</td>
<td>$29.0</td>
</tr>
<tr>
<td>Buildings and building improvements</td>
<td>188.8</td>
</tr>
<tr>
<td>Machinery and equipment</td>
<td>712.1</td>
</tr>
<tr>
<td>Software</td>
<td>404.9</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>196.5</td>
</tr>
<tr>
<td>Furniture and fixtures</td>
<td>58.1</td>
</tr>
<tr>
<td>Construction in progress</td>
<td>127.9</td>
</tr>
<tr>
<td>Equipment and real estate under capital leases</td>
<td>14.6</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization of capital lease assets</td>
<td>(1,024.5)</td>
</tr>
<tr>
<td>Total</td>
<td>$707.4</td>
</tr>
</tbody>
</table>

Depreciation expense and amortization of property, plant and equipment was $144.7, $141.1 and $141.5 for 2013, 2012 and 2011, respectively, including software depreciation of $39.3, $35.1, and $34.0 for 2013, 2012 and 2011, respectively.
8. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill (net of accumulated amortization) for the years ended December 31, 2013 and 2012 are as follows:

<table>
<thead>
<tr>
<th>Clinical Diagnostics Laboratory Segment</th>
<th>Other Segment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>December 31, 2013</strong></td>
<td><strong>December 31, 2012</strong></td>
<td><strong>December 31, 2013</strong></td>
</tr>
<tr>
<td>Balance as of January 1</td>
<td>$2,857.1</td>
<td>$2,643.5</td>
</tr>
<tr>
<td>Goodwill acquired during the period</td>
<td>107.5</td>
<td>219.1</td>
</tr>
<tr>
<td>Adjustments to goodwill</td>
<td>(4.4)</td>
<td>(5.5)</td>
</tr>
<tr>
<td><strong>Balance at end of period</strong></td>
<td>$2,960.2</td>
<td>$2,857.1</td>
</tr>
</tbody>
</table>

The components of identifiable intangible assets are as follows:

<table>
<thead>
<tr>
<th>Gross Carrying Amount</th>
<th>Accumulated Amortization</th>
<th>Net Carrying Amount</th>
<th>Gross Carrying Amount</th>
<th>Accumulated Amortization</th>
<th>Net Carrying Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Customer relationships</td>
<td>$1,327.0</td>
<td>$(545.1)</td>
<td>$781.9</td>
<td>$1,296.1</td>
<td>$(483.3)</td>
</tr>
<tr>
<td>Patents, licenses and technology</td>
<td>116.2</td>
<td>(85.4)</td>
<td>30.8</td>
<td>117.2</td>
<td>(76.2)</td>
</tr>
<tr>
<td>Non-compete agreements</td>
<td>41.6</td>
<td>(25.3)</td>
<td>16.3</td>
<td>32.3</td>
<td>(19.6)</td>
</tr>
<tr>
<td>Trade names</td>
<td>131.4</td>
<td>(83.0)</td>
<td>48.4</td>
<td>131.3</td>
<td>(73.4)</td>
</tr>
<tr>
<td>Canadian licenses</td>
<td>694.6</td>
<td>—</td>
<td>694.6</td>
<td>743.3</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$2,310.8</td>
<td>$(738.8)</td>
<td>$1,572.0</td>
<td>$2,320.2</td>
<td>$(652.5)</td>
</tr>
</tbody>
</table>

A summary of amortizable intangible assets acquired during 2013, and their respective weighted average amortization periods are as follows:

<table>
<thead>
<tr>
<th>Amortizable Intangible Assets</th>
<th>Weighted-Average Amortization Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Customer relationships</td>
<td>16.2</td>
</tr>
<tr>
<td>Non-compete agreements</td>
<td>5.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>13.7</td>
</tr>
</tbody>
</table>

Amortization of intangible assets was $81.7, $86.3 and $85.8 in 2013, 2012 and 2011, respectively. During 2012, the Company recorded $6.2 accelerated amortization expense relating to the termination of a technology licensing agreement. Amortization expense of intangible assets is estimated to be $84.7 in fiscal 2014, $81.3 in fiscal 2015, $75.9 in fiscal 2016, $68.7 in fiscal 2017, $58.4 in fiscal 2018, and $504.7 thereafter.

The Company paid $0.0, $2.5 and $0.0 in 2013, 2012 and 2011 for certain exclusive and non-exclusive licensing rights to diagnostic testing technology. These amounts are being amortized over the life of the licensing agreements.

9. Accrued Expenses and Other

<table>
<thead>
<tr>
<th>Expense Description</th>
<th>December 31, 2013</th>
<th>December 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee compensation and benefits</td>
<td>$166.0</td>
<td>$158.0</td>
</tr>
<tr>
<td>Self-insurance reserves</td>
<td>33.3</td>
<td>34.2</td>
</tr>
<tr>
<td>Accrued taxes payable</td>
<td>24.2</td>
<td>24.0</td>
</tr>
<tr>
<td>Royalty and license fees payable</td>
<td>8.1</td>
<td>13.8</td>
</tr>
<tr>
<td>Restructuring reserves</td>
<td>9.3</td>
<td>8.4</td>
</tr>
<tr>
<td>Acquisition related reserves</td>
<td>14.2</td>
<td>11.5</td>
</tr>
<tr>
<td>Interest payable</td>
<td>19.7</td>
<td>24.0</td>
</tr>
<tr>
<td>Other</td>
<td>35.2</td>
<td>37.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$310.0</td>
<td>$311.6</td>
</tr>
</tbody>
</table>
10. Other Liabilities

<table>
<thead>
<tr>
<th>December 31,</th>
<th>December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td>Post-retirement benefit obligation</td>
<td>$60.6</td>
</tr>
<tr>
<td>Defined benefit plan obligation</td>
<td>80.0</td>
</tr>
<tr>
<td>Restructuring reserves</td>
<td>16.4</td>
</tr>
<tr>
<td>Self-insurance reserves</td>
<td>31.6</td>
</tr>
<tr>
<td>Acquisition related reserves</td>
<td>7.2</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>4.0</td>
</tr>
<tr>
<td>Other</td>
<td>66.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$266.5</strong></td>
</tr>
</tbody>
</table>

11. Debt

Short-term borrowings and current portion of long-term debt at December 31, 2013 and 2012 consisted of the following:

<table>
<thead>
<tr>
<th>December 31,</th>
<th>December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td>Zero-coupon convertible subordinated notes</td>
<td>$710.8</td>
</tr>
<tr>
<td>5.5% Senior Notes due 2013</td>
<td>–</td>
</tr>
<tr>
<td>Capital lease obligation</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Total short-term borrowings and current portion of long-term debt</strong></td>
<td><strong>$111.3</strong></td>
</tr>
</tbody>
</table>

Long-term debt at December 31, 2013 and 2012 consisted of the following:

<table>
<thead>
<tr>
<th>December 31,</th>
<th>December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>2012</td>
</tr>
<tr>
<td>5.625% Senior Notes due 2015</td>
<td>$250.0</td>
</tr>
<tr>
<td>3.125% Senior Notes due 2016</td>
<td>325.0</td>
</tr>
<tr>
<td>2.20% Senior Notes due 2017</td>
<td>500.0</td>
</tr>
<tr>
<td>2.50% Senior Notes due 2018</td>
<td>400.0</td>
</tr>
<tr>
<td>4.625% Senior Notes due 2020</td>
<td>600.0</td>
</tr>
<tr>
<td>3.75% Senior Notes due 2022</td>
<td>500.0</td>
</tr>
<tr>
<td>4.00% Senior Notes due 2023</td>
<td>300.0</td>
</tr>
<tr>
<td>Capital leases</td>
<td>14.1</td>
</tr>
<tr>
<td><strong>Total long-term debt</strong></td>
<td><strong>$2,889.1</strong></td>
</tr>
</tbody>
</table>

Credit Facilities

On December 21, 2011, the Company entered into a Credit Agreement (the “Credit Agreement”) providing for a five-year $1,000.0 senior unsecured revolving credit facility (the “Revolving Credit Facility”) with Bank of America, N.A., acting as Administrative Agent, Barclays Capital as Syndication Agent, and a group of financial institutions as lending parties. As part of the Revolving Credit Facility, the Company repaid all of the outstanding principal balances of $318.8 on its existing term loan facility and $235.0 on its existing revolving credit facility. In conjunction with the repayment and cancellation of its old credit facility, the Company recorded approximately $1.0 of remaining unamortized debt costs as interest expense in the accompanying Consolidated Statements of Operations for the year ended December 31, 2011.

There were no balances outstanding on the Company’s Revolving Credit Facility at December 31, 2013 or December 31, 2012. The Revolving Credit Facility bears interest at varying rates based upon a base rate or LIBOR plus (in each case) a percentage based on the Company’s debt rating with Standard & Poor’s and Moody’s Rating Services.

The Revolving Credit Facility is available for general corporate purposes, including working capital, capital expenditures, acquisitions, funding of share repurchases and other restricted payments permitted under the Credit Agreement. The Credit Agreement also contains limitations on aggregate subsidiary indebtedness and a debt covenant that requires that the Company maintain on the last day of any period of four consecutive fiscal quarters, in each case taken as one accounting period, a ratio of total debt to consolidated EBITDA of not more than 3.0 to 1.0. The Company was in compliance with all covenants in the Credit Agreement at December 31, 2013. As of December 31, 2013, the ratio of total debt to consolidated EBITDA was 2.4.

As of December 31, 2013, the effective interest rate on the Revolving Credit Facility was 1.1%.

Zero-Coupon Convertible Subordinated Notes

The Company had $128.8 and $154.3 aggregate principal amount at maturity of zero-coupon convertible subordinated notes (the “notes”) due 2021 outstanding at December 31, 2013 and 2012, respectively. The notes, which are subordinate to the Company’s bank debt, were sold at an issue price of $671.65 per $1,000 principal amount at maturity (representing a yield to maturity of 2.0% per year). Each one thousand dollar principal amount at maturity of the notes is convertible into 13.4108 shares of the Company’s common stock, subject to adjustment in certain circumstances, if one of the following conditions occurs:

1) If the sales price of the Company’s common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the preceding quarter reaches specified thresholds (beginning at 120% and declining 0.1282% per quarter until it reaches approximately 110% for the quarter beginning July 1, 2021 of the accreted conversion price per share of common stock on the last day of the preceding quarter). The accreted conversion price per share will equal the issue price of a note plus the accrued original issue discount and any accrued
contingent additional principal, divided by the number of shares of common stock issuable upon conversion of a note on that day. The conversion trigger price for the fourth quarter of 2013 was $72.55.

2) If the credit rating assigned to the notes by Standard & Poor’s Ratings Services is at or below BB-.
3) If the notes are called for redemption.
4) If specified corporate transactions have occurred (such as if the Company is party to a consolidation, merger or binding share exchange or a transfer of all or substantially all of its assets).

The Company may redeem for cash all or a portion of the notes at any time at specified redemption prices per one thousand dollar principal amount at maturity of the notes.

The Company has registered the notes and the shares of common stock issuable upon conversion of the notes with the Securities and Exchange Commission.

During 2013 and 2012, the Company settled notices to convert $25.5 and $9.8 aggregate principal amount at maturity of its zero-coupon subordinated notes with a conversion value of $31.8 and $12.0, respectively. The total cash used for these settlements was $21.5 and $8.2 and the Company also issued 0.1 and 0.0 additional shares of common stock, respectively. As a result of these conversions, in 2013 and 2012 the Company reversed approximately $3.4 and $0.6, respectively, of deferred tax liability to reflect the tax benefit realized upon issuance of the shares.

On September 12, 2013, the Company announced that for the period of September 12, 2013 to March 11, 2014, the zero-coupon subordinated notes will accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a zero-coupon subordinated note for the five trading days ended September 6, 2013, in addition to the continued accrual of the original issue discount.

On January 2, 2014, the Company announced that its zero-coupon subordinated notes may be converted into cash and common stock at the conversion rate of 13.4108 per $1,000 principal amount at maturity of the notes, subject to the terms of the zero-coupon subordinated notes and the Indenture, dated as of October 24, 2006 between the Company and The Bank of New York Mellon, as trustee and conversion agent. In order to exercise the option to convert all or a portion of the zero-coupon subordinated notes, holders are required to validly surrender their zero-coupon subordinated notes at any time during the calendar quarter beginning January 1, 2014, through the close of business on the last business day of the calendar quarter, which is 5:00 p.m., New York City time, on Monday, March 31, 2014. If notices of conversion are received, the Company plans to settle the cash portion of the conversion obligation with cash on hand and/or borrowings under the revolving credit facility.

Senior Notes

On November 1, 2013, the Company issued $700.0 in new senior notes pursuant to the Company’s effective shelf registration on Form S-3. The new senior notes consisted of $400.0 aggregate principal amount of 2.50% Senior Notes due 2018 and $300.0 aggregate principal amount of 4.00% Senior Notes due 2023. The net proceeds were used to repay all of the outstanding borrowings under the Company’s Revolving Credit Facility and for general corporate purposes.

The Senior Notes due 2018 and Senior Notes due 2023 bear interest at the rate of 2.50% per annum and 4.00% per annum, respectively, payable semi-annually on November 1 and May 1 of each year, commencing on May 1, 2014.

During the third quarter of 2013, the Company entered into two fixed-to-variable interest rate swap agreements for the 4.625% senior notes due 2020 with an aggregate notional amount of $600.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company’s long term debt. These derivative financial instruments are accounted for as fair value hedges of the senior notes due 2020. These interest rate swaps are included in other long term assets or liabilities, as applicable, and added to the value of the senior notes, with an aggregate fair value of $0.0 at December 31, 2013.

On August 23, 2012, the Company issued $1,000.0 in new senior notes pursuant to the Company’s effective shelf registration statement on Form S-3. The new senior notes consisted of $500.0 aggregate principal amount of 2.20% Senior Notes due 2017 and $500.0 aggregate principal amount of 3.75% Senior Notes due 2022. The net proceeds were used to repay $625.0 of the outstanding borrowings under the Company’s Revolving Credit Facility. The remaining proceeds were available for other general corporate purposes.

The Senior Notes due 2017 and Senior Notes due 2022 bear interest at the rate of 2.20% per annum and 3.75% per annum, respectively, payable semi-annually on February 23 and August 23 of each year, commencing February 23, 2013.
On October 28, 2010, in conjunction with the acquisition of Genzyme Genetics, the Company entered into a $925.0 Bridge Term Loan Credit Agreement, among the Company, the lenders named therein and Citibank, N.A., as administrative agent (the “Bridge Facility”). The Company replaced and terminated the Bridge Facility in November 2010 by making an offering in the debt capital markets. On November 19, 2010, the Company sold $925.0 in debt securities, consisting of $325.0 aggregate principal amount of 3.125% Senior Notes due May 15, 2016 and $600.0 aggregate principal amount of 4.625% Senior Notes due November 15, 2020. Beginning on May 15, 2011, interest on the Senior Notes due 2016 and 2020 is payable semi-annually on May 15, and November 15.

On December 1, 2010, the acquisition of Genzyme Genetics was funded by the net proceeds from the issuance of these Notes ($915.4) and with cash on hand.

The Senior Notes due 2015 bear interest at the rate of 5.625% per annum from December 14, 2005, payable semi-annually on June 15 and December 15.

The scheduled payments of long term debt and future minimum lease payments for capital leases at the end of 2013 are summarized as follows:

<table>
<thead>
<tr>
<th>Notes and Capital Leases</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$ 110.8</td>
</tr>
<tr>
<td>2015</td>
<td>250.0</td>
</tr>
<tr>
<td>2016</td>
<td>325.0</td>
</tr>
<tr>
<td>2017</td>
<td>500.0</td>
</tr>
<tr>
<td>2018</td>
<td>400.0</td>
</tr>
<tr>
<td>Thereafter</td>
<td>1,400.0</td>
</tr>
<tr>
<td></td>
<td>2,985.8</td>
</tr>
<tr>
<td></td>
<td>29.3</td>
</tr>
<tr>
<td></td>
<td>(14.7)</td>
</tr>
<tr>
<td></td>
<td>(14.7)</td>
</tr>
<tr>
<td>Total long-term debt</td>
<td>2,985.8</td>
</tr>
<tr>
<td>Less current portion</td>
<td>(110.8)</td>
</tr>
<tr>
<td></td>
<td>(0.5)</td>
</tr>
<tr>
<td></td>
<td>(111.3)</td>
</tr>
<tr>
<td>Long-term debt, due beyond one year</td>
<td>$2,875.0</td>
</tr>
</tbody>
</table>

12. Preferred Stock and Common Shareholders’ Equity

The Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company’s treasury shares are recorded at aggregate cost. Common shares issued and outstanding are summarized in the following table:

<table>
<thead>
<tr>
<th>Common shares issued</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common stock issued at January 1</td>
<td>175.8</td>
<td>120.0</td>
<td>124.5</td>
</tr>
<tr>
<td>Common stock issued under employee stock plans</td>
<td>2.6</td>
<td>1.6</td>
<td>1.9</td>
</tr>
<tr>
<td>Common stock issued upon conversion of zero-coupon subordinated notes</td>
<td>0.1</td>
<td>–</td>
<td>1.0</td>
</tr>
<tr>
<td>Retirement of common stock</td>
<td>(10.4)</td>
<td>(5.8)</td>
<td>(7.4)</td>
</tr>
<tr>
<td>Common stock issued at December 31</td>
<td>108.1</td>
<td>115.8</td>
<td>120.0</td>
</tr>
</tbody>
</table>

The changes in common shares issued and held in treasury are summarized below:

<table>
<thead>
<tr>
<th>Common shares held in treasury</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common shares held in treasury at January 1</td>
<td>22.3</td>
<td>22.2</td>
<td>22.1</td>
</tr>
<tr>
<td>Surrender of restricted stock and performance share awards</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Common shares held in treasury at December 31</td>
<td>22.4</td>
<td>22.3</td>
<td>22.2</td>
</tr>
</tbody>
</table>

Share Repurchase Program

During 2013, the Company purchased 10.4 shares of its common stock at a total cost of $1,015.6. As of December 31, 2013, the Company had outstanding authorization from the Board of Directors to purchase $1,058.5 of Company common stock.

Accumulated Other Comprehensive Earnings

The components of accumulated other comprehensive earnings are as follows:

<table>
<thead>
<tr>
<th>Accumulated Other Comprehensive Earnings</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at December 31, 2010</td>
<td>$ 152.8</td>
<td>$ (62.9)</td>
<td>$ (1.4)</td>
</tr>
<tr>
<td>Current year adjustments</td>
<td>(13.2)</td>
<td>(65.3)</td>
<td>(2.4)</td>
</tr>
<tr>
<td>Amounts reclassified from accumulated other comprehensive income</td>
<td>–</td>
<td>7.8</td>
<td>(76.1)</td>
</tr>
<tr>
<td>Tax effect of adjustments</td>
<td>3.9</td>
<td>22.4</td>
<td>(1.0)</td>
</tr>
<tr>
<td>Balance at December 31, 2011</td>
<td>143.5</td>
<td>(98.0)</td>
<td>45.5</td>
</tr>
<tr>
<td>Current year adjustments</td>
<td>31.3</td>
<td>(48.0)</td>
<td>26.5</td>
</tr>
<tr>
<td>Amounts reclassified from accumulated other comprehensive income</td>
<td>–</td>
<td>12.1</td>
<td>12.1</td>
</tr>
<tr>
<td>Tax effect of adjustments</td>
<td>(11.9)</td>
<td>(2.8)</td>
<td>(14.7)</td>
</tr>
<tr>
<td>Balance at December 31, 2012</td>
<td>162.9</td>
<td>(93.5)</td>
<td>69.4</td>
</tr>
<tr>
<td>Current year adjustments</td>
<td>(63.2)</td>
<td>31.6</td>
<td>15.2</td>
</tr>
<tr>
<td>Amounts reclassified from accumulated other comprehensive income</td>
<td>–</td>
<td>10.5</td>
<td>10.5</td>
</tr>
<tr>
<td>Tax effect of adjustments</td>
<td>23.5</td>
<td>(15.7)</td>
<td>(6.3)</td>
</tr>
<tr>
<td>Balance at December 31, 2013</td>
<td>$ 123.2</td>
<td>(67.1)</td>
<td>$ 10.1</td>
</tr>
</tbody>
</table>

(a) The amortization of prior service cost is included in the computation of net periodic benefit cost. Refer to Note 16 Pension and Postretirement Plans for additional information regarding the Company’s net periodic benefit cost.
13. Income Taxes

The sources of income before taxes, classified between domestic and foreign entities are as follows:

<table>
<thead>
<tr>
<th>Pre-Tax Income</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domestic</td>
<td>$844.2</td>
<td>$909.0</td>
<td>$834.0</td>
</tr>
<tr>
<td>Foreign</td>
<td>71.4</td>
<td>35.2</td>
<td>32.1</td>
</tr>
<tr>
<td>Total pre-tax income</td>
<td>$915.6</td>
<td>$944.2</td>
<td>$866.1</td>
</tr>
</tbody>
</table>

The provisions for income taxes in the accompanying consolidated statements of operations consist of the following:

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current: Federal</td>
<td>$231.6</td>
<td>$254.1</td>
<td>$269.7</td>
</tr>
<tr>
<td>State</td>
<td>29.9</td>
<td>35.1</td>
<td>54.3</td>
</tr>
<tr>
<td>Foreign</td>
<td>22.5</td>
<td>16.9</td>
<td>6.8</td>
</tr>
<tr>
<td>Total current</td>
<td>$284.0</td>
<td>$306.3</td>
<td>$330.8</td>
</tr>
<tr>
<td>Deferred: Federal</td>
<td>$ 55.2</td>
<td>$ 58.3</td>
<td>$ 5.0</td>
</tr>
<tr>
<td>State</td>
<td>6.1</td>
<td>0.4</td>
<td>(4.4)</td>
</tr>
<tr>
<td>Foreign</td>
<td>(5.1)</td>
<td>(5.4)</td>
<td>1.6</td>
</tr>
<tr>
<td>Total deferred</td>
<td>56.2</td>
<td>53.3</td>
<td>2.2</td>
</tr>
<tr>
<td>Net deferred tax assets</td>
<td>$340.2</td>
<td>$359.4</td>
<td>$333.0</td>
</tr>
</tbody>
</table>

A portion of the tax benefit associated with option exercises from stock plans reducing taxes currently payable are recorded through additional paid-in capital. The benefits recorded through additional paid-in capital are approximately $10.6, $8.4 and $11.0 in 2013, 2012 and 2011, respectively.

The effective tax rates on earnings before income taxes are reconciled to statutory federal income tax rates as follows:

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statutory federal rate</td>
<td>35.0%</td>
<td>35.0%</td>
<td>35.0%</td>
</tr>
<tr>
<td>State and local income taxes, net of federal income tax effect</td>
<td>2.6</td>
<td>2.4</td>
<td>3.7</td>
</tr>
<tr>
<td>Other</td>
<td>(0.4)</td>
<td>0.7</td>
<td>(0.3)</td>
</tr>
<tr>
<td>Effective rate</td>
<td>37.2%</td>
<td>38.1%</td>
<td>38.4%</td>
</tr>
</tbody>
</table>

The effective tax rate for 2013 was favorably impacted by the release of the capital loss valuation allowance and recording two years of the R&D tax credit. The American Taxpayer Relief Act of 2012 was enacted in early 2013 and reinstated the R&D tax credit for 2012 and extended the credit for calendar year 2013.

The effective tax rate for 2012 was favorably impacted by a decrease in the reserve for unrecognized income tax benefits compared to 2011, partially offset by an increase in tax on the additional investment in the Company’s Canadian subsidiary. The effective tax rate for 2011 was negatively impacted by an increase in the reserve for unrecognized income tax benefits, the divestiture of certain Orchid paternity contracts, and foreign losses not tax effected.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

<table>
<thead>
<tr>
<th>December 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferred tax assets: Accounts receivable</td>
<td>$ 20.2</td>
<td>$ 25.0</td>
</tr>
<tr>
<td>Employee compensation and benefits</td>
<td>83.4</td>
<td>114.4</td>
</tr>
<tr>
<td>Self insurance reserves</td>
<td>17.8</td>
<td>17.0</td>
</tr>
<tr>
<td>Postretirement benefit obligation</td>
<td>23.2</td>
<td>23.3</td>
</tr>
<tr>
<td>Acquisition and restructuring reserves</td>
<td>20.6</td>
<td>18.5</td>
</tr>
<tr>
<td>Tax loss carryforwards</td>
<td>58.0</td>
<td>66.3</td>
</tr>
<tr>
<td>Other</td>
<td>3.8</td>
<td>2.1</td>
</tr>
<tr>
<td>Total gross deferred tax liabilities</td>
<td>(749.5)</td>
<td>(737.3)</td>
</tr>
<tr>
<td>Net deferred tax liabilities</td>
<td>($539.0)</td>
<td>($489.1)</td>
</tr>
</tbody>
</table>

The valuation allowance decreased from $18.4 in 2012 to $16.5 in 2013. The decrease in the valuation allowance is primarily due to a current year capital gain resulting from the disposition of a minority investment. A capital loss carryover with a full valuation allowance was released to offset substantially all of the 2013 capital gain income.

The Company has foreign tax loss carryovers of $11.8 with a full valuation allowance. Most of the foreign losses have an indefinite carryover. The Company has federal tax loss carryovers of approximately $44.2 expiring periodically through 2031. The utilization of the tax loss carryovers is limited due to change of ownership rules. However, at this time the Company expects to fully utilize substantially all federal tax loss carryovers. In addition to the net operating losses, the Company has a foreign capital loss carryover of $1.9. The loss has an indefinite life and has a full valuation allowance.

The gross unrecognized income tax benefits were $25.6 and $36.4 at December 31, 2013 and 2012, respectively. It is anticipated that the amount of the unrecognized income tax benefits will
change within the next twelve months; however, these changes are not expected to have a significant impact on the results of operations, cash flows or the financial position of the Company.

The Company recognizes interest and penalties related to unrecognized income tax benefits in income tax expense. Accrued interest and penalties related to uncertain tax positions totaled $9.3 and $9.8 as of December 31, 2013 and 2012, respectively. During the years ended December 31, 2013, 2012 and 2011, the Company recognized $2.4, $3.0 and $3.5, respectively, in interest and penalties expense, which was offset by a benefit of $2.9, $3.9 and $4.9, respectively.

The following table shows a reconciliation of the unrecognized income tax benefits from uncertain tax positions for the years ended December 31, 2013, 2012 and 2011:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance as of January 1</td>
<td>$36.4</td>
<td>$52.7</td>
<td>$53.6</td>
</tr>
<tr>
<td>Increase in reserve for tax positions taken in the current year</td>
<td>1.9</td>
<td>0.4</td>
<td>8.6</td>
</tr>
<tr>
<td>Decrease in reserve for tax positions taken in a prior period</td>
<td>–</td>
<td>(8.0)</td>
<td>–</td>
</tr>
<tr>
<td>Decrease in reserve as a result of settlements reached with tax authorities</td>
<td>(4.4)</td>
<td>(0.1)</td>
<td>(0.2)</td>
</tr>
<tr>
<td>Decrease in reserve as a result of lapses in the statute of limitations</td>
<td>(8.3)</td>
<td>(8.6)</td>
<td>(9.3)</td>
</tr>
<tr>
<td>Balance as of December 31</td>
<td>$25.6</td>
<td>$36.4</td>
<td>$52.7</td>
</tr>
</tbody>
</table>

As of December 31, 2013 and 2012, $25.6 and $37.1, respectively, is the approximate amount of unrecognized income tax benefits that, if recognized, would favorably affect the effective income tax rate in any future periods.

The Company has substantially concluded all U.S. federal income tax matters for years through 2011. Substantially all material state and local, and foreign income tax matters have been concluded through 2008 and 2001, respectively.

The Internal Revenue Service concluded the examination of the Company’s 2010 and 2011 income tax returns during 2013. The Company has various state income tax examinations ongoing throughout the year. Canada Revenue Agency is conducting an audit of the 2009 and 2010 Canadian income tax return. The Company believes adequate provisions have been recorded related to all open tax years.

Substantially all of the profitable foreign earnings are repatriated on an annual basis and U.S. income taxes have been provided accordingly. The unremitted foreign earnings as of December 31, 2013 are approximately $17.7. If repatriated to the U.S., the incremental U.S. tax, net of any underlying foreign tax credit, would have increased the Company’s overall income tax by approximately $0.5.

### 14. Stock Compensation Plans

#### Stock Incentive Plans

There are currently 10.2 shares authorized for issuance under the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan and at December 31, 2013 there were 6.7 additional shares available for grant under the Plan. This Plan was approved by shareholders at the 2012 annual meeting.

#### Stock Options

The following table summarizes grants of non-qualified options made by the Company to officers, key employees, and non-employee directors under all plans. Stock options are generally granted at an exercise price equal to or greater than the fair market price per share on the date of grant. Also, for each grant, options vest ratably over a period of three years on the anniversaries of the grant date, subject to their earlier expiration or termination.

Changes in options outstanding under the plans for the period indicated were as follows:

<table>
<thead>
<tr>
<th></th>
<th>Number of Options</th>
<th>Weighted-Average Exercise Price per Option</th>
<th>Weighted-Average Remaining Contractual Term</th>
<th>Aggregate Intrinsic Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding at December 31, 2012</td>
<td>6.9</td>
<td>$77.62</td>
<td></td>
<td>$51.5</td>
</tr>
<tr>
<td>Granted</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Exercised</td>
<td>(2.2)</td>
<td>72.02</td>
<td></td>
<td>$51.3</td>
</tr>
<tr>
<td>Cancelled</td>
<td>(0.1)</td>
<td>82.92</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Outstanding at December 31, 2013</td>
<td>4.6</td>
<td>$80.18</td>
<td>6.4</td>
<td>$51.5</td>
</tr>
<tr>
<td>Vested and expected to vest at December 31, 2013</td>
<td>4.5</td>
<td>$80.13</td>
<td>6.4</td>
<td>$51.5</td>
</tr>
<tr>
<td>Exercisable at December 31, 2013</td>
<td>3.1</td>
<td>$77.06</td>
<td>5.7</td>
<td>$44.2</td>
</tr>
</tbody>
</table>

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company’s closing stock price on the last trading day of 2013 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2013. The amount of intrinsic value will change based on the fair market value of the Company’s stock.
Cash received by the Company from option exercises, the actual tax benefit realized for the tax deductions and the aggregate intrinsic value of options exercised from option exercises under all share-based payment arrangements during the years ended December 31, 2013, 2012, and 2011 were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash received by the Company</td>
<td>$158.0</td>
<td>$69.4</td>
<td>$106.1</td>
</tr>
<tr>
<td>Tax benefits realized</td>
<td>$21.3</td>
<td>$9.7</td>
<td>$17.7</td>
</tr>
<tr>
<td>Aggregate intrinsic value</td>
<td>$55.4</td>
<td>$35.3</td>
<td>$45.5</td>
</tr>
</tbody>
</table>

The following table summarizes information concerning currently outstanding and exercisable options:

<table>
<thead>
<tr>
<th>Range of Exercise Prices</th>
<th>Options Outstanding</th>
<th>Options Exercisable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number Outstanding</td>
<td>Weighted-Average</td>
</tr>
<tr>
<td>$ 6.80 – 59.37</td>
<td>0.1</td>
<td>1.6</td>
</tr>
<tr>
<td>$59.38 – 67.60</td>
<td>0.4</td>
<td>5.1</td>
</tr>
<tr>
<td>$67.61 – 75.63</td>
<td>1.1</td>
<td>5.3</td>
</tr>
<tr>
<td>$75.64 – 80.37</td>
<td>0.4</td>
<td>3.4</td>
</tr>
<tr>
<td>$80.38 – 98.49</td>
<td>2.6</td>
<td>7.8</td>
</tr>
<tr>
<td></td>
<td>4.6</td>
<td>6.4</td>
</tr>
</tbody>
</table>

The following table shows the weighted average grant-date fair values of options issued during the respective year and the weighted average assumptions that the Company used to develop the fair value estimates:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value per option</td>
<td>N/A</td>
<td>$13.43</td>
<td>$17.06</td>
</tr>
<tr>
<td>Valuation assumptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average expected life (in years)</td>
<td>N/A</td>
<td>3.4</td>
<td>3.4</td>
</tr>
<tr>
<td>Risk-free interest rate</td>
<td>N/A</td>
<td>0.4%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Expected volatility</td>
<td>N/A</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Expected dividend yield</td>
<td>N/A</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

The Black Scholes model incorporates assumptions to value stock-based awards. The risk-free interest rate for periods within the contractual life of the option is based on a zero-coupon U.S. government instrument over the contractual term of the equity instrument. Expected volatility of the Company's stock is based on historical volatility of the Company's stock. The Company uses historical data to calculate the expected life of the option. Groups of employees and non-employee directors that have similar exercise behavior with regard to option exercise timing and forfeiture rates are considered separately for valuation purposes. For 2013, 2012 and 2011, expense related to the Company's stock option plan totaled $14.5, $21.5 and $24.9, respectively. The Company did not grant any options to employees during 2013.

### Restricted Stock, Restricted Stock Units and Performance Shares

The Company grants restricted stock, restricted stock units and performance shares (“non-vested shares”) to officers, key employees, and non-employee directors under all plans. Restricted stock and restricted stock units become vested annually in equal one-third increments beginning on the first anniversary of the grant. A performance share grant in 2011 represents a three-year award opportunity for the period 2011-2013 and becomes vested in the first quarter of 2014. A performance share grant in 2012 represents a three year award opportunity for the period of 2012-2014 and becomes vested in the first quarter of 2015. A performance share grant in 2013 represents a three-year award opportunity for the period of 2013-2015 and becomes vested in the first quarter of 2016. Performance share awards are subject to certain earnings per share, revenue, operating income, earnings before income taxes and total shareholder return targets, the achievement of which may increase or decrease the number of shares which the grantee receives upon vesting. The unearned restricted stock and performance share compensation is being amortized to expense over the applicable vesting periods. For 2013, 2012 and 2011, total restricted stock, restricted stock units and performance share compensation expense was $19.3, $14.3 and $21.3, respectively.
The following table shows a summary of non-vested shares for the year ended December 31, 2013:

<table>
<thead>
<tr>
<th></th>
<th>Number of Shares</th>
<th>Weighted-Average Grant Date Fair Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-vested at January 1, 2013</td>
<td>0.6</td>
<td>$84.91</td>
</tr>
<tr>
<td>Granted</td>
<td>0.5</td>
<td>90.19</td>
</tr>
<tr>
<td>Vested</td>
<td>(0.2)</td>
<td>75.79</td>
</tr>
<tr>
<td>Canceled</td>
<td>(0.1)</td>
<td>90.43</td>
</tr>
<tr>
<td>Non-vested at December 31, 2013</td>
<td>0.8</td>
<td>$90.70</td>
</tr>
</tbody>
</table>

As of December 31, 2013, there was $28.5 of total unrecognized compensation cost related to non-vested restricted stock and performance share-based compensation arrangements granted under the stock incentive plans. That cost is expected to be recognized over a weighted average period of 1.8 years.

### Employee Stock Purchase Plan

The Company has an employee stock purchase plan, begun in 1997 and amended in 1999, 2004, 2008 and 2012, with 6.3 shares of common stock authorized for issuance. The plan permits substantially all employees to purchase a limited number of shares of Company stock at 85% of market value. The Company issues shares to participating employees semi-annually in January and July of each year. Approximately 0.2 shares were purchased by eligible employees in 2013, 2012 and 2011, respectively. For 2013, 2012 and 2011, expense related to the Company’s employee stock purchase plan was $3.5, $4.9 and $2.7, respectively.

The Company uses the Black-Scholes model to calculate the fair value of the employee’s purchase right. The fair value of the employee’s purchase right and the assumptions used in its calculation are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value of the employee’s purchase right</td>
<td>$17.22</td>
<td>$23.02</td>
<td>$15.58</td>
</tr>
<tr>
<td>Valuation assumptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk-free interest rate</td>
<td>0.1%</td>
<td>0.1%</td>
<td>0.1%</td>
</tr>
<tr>
<td>Expected volatility</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Expected dividend yield</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

### 15. Commitments and Contingent Liabilities

The Company is involved from time to time in various claims and legal actions, including arbitrations, class actions, and other litigation (including those described in more detail below), arising in the ordinary course of business. Some of these actions involve claims that are substantial in amount. These matters include, but are not limited to, intellectual property disputes, professional liability, employee related matters, and inquiries, including subpoenas and other civil investigative demands, from governmental agencies and Medicare or Medicaid payers and managed care payers reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company receives civil investigative demands or other inquiries from various governmental bodies in the ordinary course of its business. Such inquiries can relate to the Company or other healthcare providers. The Company works cooperatively to respond to appropriate requests for information.

The Company is also named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from federal or state health care programs. The suits may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the qui tam plaintiff. Such claims are an inevitable part of doing business in the health care field today.

The Company believes that it is in compliance in all material respects with all statutes, regulations and other requirements applicable to its clinical laboratory operations. The clinical laboratory testing industry is, however, subject to extensive regulation, and the courts have not interpreted many of these statutes and regulations. There can be no assurance therefore that those applicable statutes and regulations will not be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant fines and the loss of various licenses, certificates and authorizations.
Many of the claims and legal actions against the Company are at preliminary stages, and many of these cases seek an indeterminate amount of damages. The Company records an aggregate legal reserve, which is determined using actuarial calculations around historical loss rates and assessment of trends experienced in settlements and defense costs. In accordance with FASB Accounting Standards Codification Topic 450 “Contingencies”, the Company establishes reserves for judicial, regulatory, and arbitration matters outside the aggregate legal reserve if and when those matters present loss contingencies that are both probable and estimable and would exceed the aggregate legal reserve. When loss contingencies are not both probable and estimable, the Company does not establish separate reserves.

The Company is unable to estimate a range of reasonably probable loss for cases described in more detail below in which damages either have not been specified or, in the Company’s judgment, are unsupported and/or exaggerated and (i) the proceedings are in early stages; (ii) there is uncertainty as to the outcome of pending appeals or motions; (iii) there are significant factual issues to be resolved; and/or (iv) there are novel legal issues to be presented. For these cases, however, the Company does not believe, based on currently available information, that the outcomes of these proceedings will have a material adverse effect on the Company's financial condition, though the outcomes could be material to the Company’s operating results for any particular period, depending, in part, upon the operating results for such period.

As previously reported, the Company reached a settlement in the previously disclosed lawsuit, *et al. v. Quest Diagnostics Incorporated, et al.* (the “Hunter Labs Settlement Agreement”), to avoid the uncertainty and costs associated with prolonged litigation. Pursuant to the executed settlement agreement, the Company recorded a litigation settlement expense of $34.5 in the second quarter of 2011 (net of a previously recorded reserve of $15.0) and paid the settlement amount of $49.5 in the third quarter of 2012. The Company also agreed to certain reporting obligations regarding its pricing for a limited time period and, at the option of the Company in lieu of such reporting obligations, to provide Medi-Cal with a discount from Medi-Cal’s otherwise applicable maximum reimbursement rate from November 1, 2011 through October 31, 2012. In June of 2012, the California legislature enacted Assembly Bill No. 1494, Section 9 of which directs the Department of Health Care Services (“DHCS”) to establish new reimbursement rates for Medi-Cal clinical laboratory services that will be based on payments made to California clinical laboratories for similar services by other third-party payers. With stakeholder input, DHCS established data elements and a format for laboratories to report payment data from comparable third-party payers. After reviewing the submitted data, DHCS will propose new reimbursement rates and solicit stakeholder input before their implementation. The bill provides that until the new rates are set through this process, Medi-Cal payments for clinical laboratory services will be reduced (in addition to a 10% payment reduction imposed by statute in 2011) by “up to 10 percent” for tests with dates of service on or after July 1, 2012, with a cap on payments set at 80% of the lowest maximum allowance established under the federal Medicare program. Under the terms of the Hunter Labs Settlement Agreement, the enactment of this new California legislation terminates the Company’s reporting obligations (or obligation to provide a discount in lieu of reporting) under that agreement. Taken together, these changes are not expected to have a material impact on the Company’s consolidated revenues or results of operations.

As previously reported, the Company responded to an October 2007 subpoena from the United States Department of Health & Human Services Office of Inspector General’s regional office in New York. On August 17, 2011, the Southern District of New York unsealed a False Claims Act lawsuit, *United States of America ex rel. NPT Associates v. Laboratory Corporation of America Holdings*, which alleges that the Company offered UnitedHealthcare kickbacks in the form of discounts in return for Medicare business. The Plaintiff’s third amended complaint further alleges that the Company’s billing practices violated False Claims Acts in fourteen states and the District of Columbia. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney’s fees, and legal expenses. Neither the U.S. government nor any state government has intervened in the lawsuit. The Company will vigorously defend the lawsuit.

In addition, the Company has received four other subpoenas since 2007 related to Medicaid billing. In February 2009, the Company received a subpoena from the Commonwealth of Virginia Office of the Attorney General requesting documents related to its billing to Virginia Medicaid. In April of 2013, the Commonwealth of Virginia Office of Attorney General closed its investigation. In October 2009, the Company received a subpoena from the State of Michigan Department of Attorney General seeking documents related to its billing to Michigan Medicaid. In June 2010, the Company received a subpoena from the State of Florida Office of the Attorney General requesting documents related to its billing to Florida Medicaid. In October 2013, the Company received a civil
On May 2, 2013, the Company was served with a False Claims Act lawsuit, State of Georgia ex rel. Hunter Laboratories, LLC and Chris Riedel v. Quest Diagnostics Incorporated, et al., filed in the State Court of Fulton County, Georgia. The lawsuit, filed by a competitor laboratory, alleges that the Company overcharged Georgia’s Medicaid program. The case has been removed to the United States District Court for the Northern District of Georgia. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney’s fees, and legal expenses. The government filed a notice declining to intervene in the case. The Company will vigorously defend the lawsuit.

On August 19, 2013, the Company was served with a False Claims Act lawsuit, Commonwealth of Virginia ex rel. Hunter Laboratories, LLC and Chris Riedel v. Quest Diagnostics Incorporated, et al., filed in the Circuit Court of Fairfax County, Virginia. The lawsuit, filed by a competitor laboratory, alleges that the Company overcharged Virginia’s Medicaid program. The case has been removed to the United States District Court for the Eastern District of Virginia. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney’s fees, and legal expenses. The government filed a notice declining to intervene in the case. The Company’s Motion to Dismiss was granted and the plaintiffs have been granted the right to replead their complaint. The Company will vigorously defend the lawsuit.

In October 2011, a putative stockholder of the Company made a letter demand through his counsel for inspection of documents related to policies and procedures concerning the Company’s Board of Directors’ oversight and monitoring of the Company’s billing and claim submission process. The letter also seeks documents prepared for or by the Board regarding allegations from the California ex rel. Hunter Laboratories, LLC et al. v. Quest Diagnostics Incorporated, et al., lawsuit and documents reviewed and relied upon by the Board in connection with the settlement of that lawsuit. The Company is responding to the request pursuant to Delaware law.

On November 18, 2011, the Company received a letter from U.S. Senators Baucus and Grassley requesting information regarding the Company’s relationships with its largest managed care customers. The letter requests information about the Company’s contracts and financial data regarding its managed care customers. Company representatives met with Senate Finance Committee staff after receiving the request and subsequently produced documents in response. The Company continues to cooperate with the request for information.

On February 27, 2012, the Company was served with a False Claims Act lawsuit, United States ex rel. Margaret Brown v. Laboratory Corporation of America Holdings and Tri-State Clinical Laboratory Services, LLC, filed in the United States District Court for the Southern District of Ohio, Western Division. The lawsuit alleges that the defendants submitted false claims for payment for laboratory testing services performed as a result of financial relationships that violated federal Stark and anti-kickback laws. The Company owned 50% of Tri-State Clinical Laboratory Services, LLC, which was dissolved in June of 2011. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney’s fees, and legal expenses. The U.S. government has not intervened in the lawsuit. The Company will vigorously defend the lawsuit.

On June 7, 2012, the Company was served with a putative class action lawsuit, Yvonne Jansky v. Laboratory Corporation of America, et al., filed in the Superior Court of the State of California, County of San Francisco. The lawsuit alleges that the defendants committed unlawful and unfair business practices, and violated various other state laws by changing screening codes to diagnostic codes on laboratory test orders, thereby resulting in customers being responsible for co-payments and other debts. The lawsuit seeks injunctive relief, actual and punitive damages, as well as recovery of attorney’s fees, and legal expenses. The Company will vigorously defend the lawsuit.

On June 7, 2012, the Company was served with a putative class action lawsuit, Ann Baker Pepe v. Genzyme Corporation and Laboratory Corporation of America Holdings, filed in the United States District Court for the District of Massachusetts. The lawsuit alleges that the defendants failed to preserve DNA samples allegedly entrusted to the defendants and thereby breached a written agreement with plaintiff and violated state laws. The lawsuit seeks injunctive relief, actual, double and treble damages, as well as recovery of attorney’s fees and legal expenses. The Company will vigorously defend the lawsuit.
Notes to Consolidated Financial Statements

On August 24, 2012, the Company was served with a putative class action lawsuit, Sandusky Wellness Center, LLC, et al. v. MEDTOX Scientific, Inc., et al., filed in the United States District Court for the District of Minnesota. The lawsuit alleges that on or about February 21, 2012, the defendants violated the federal Telephone Consumer Protection Act by sending unsolicited facsimiles to Plaintiff and more than 39 other recipients without the recipients’ prior express invitation or permission. The lawsuit seeks actual damages or the sum of $0.0005 for each violation, subject to trebling under TCPA, and injunctive relief. The Company will vigorously defend the lawsuit.

The Company was a defendant in two separate putative class action lawsuits, Christine Bohlander v. Laboratory Corporation of America, et al., and Jemuel Andres, et al. v. Laboratory Corporation of America Holdings, et al., related to overtime pay. After the filing of the two lawsuits on July 8, 2013, the Bohlander lawsuit was consolidated into the Andres lawsuit, and the consolidated lawsuit is now pending in the Superior Court of California for the County of Los Angeles. In the consolidated lawsuit, the Plaintiffs allege on behalf of similarly situated phlebotomists and couriers that the Company failed to pay overtime, failed to provide meal and rest breaks, and committed other violations of the California Labor Code. The complaint seeks monetary damages, civil penalties, costs, injunctive relief, and attorney’s fees. The Company intends to vigorously defend the lawsuit.

On December 17, 2010, the Company was served with a lawsuit, Oliver Wuth, et al. v. Laboratory Corporation of America, et al., filed in the State Superior Court of King County, Washington. The lawsuit alleges that the Company was negligent in the handling of a prenatal genetic test order that allegedly resulted in the parents being given incorrect information. The matter was tried to a jury beginning on October 21, 2013. On December 10, 2013, the jury returned a verdict in in plaintiffs’ favor in the amount of $50.0, with 50% of liability apportioned to the Company and 50% of liability apportioned to co-defendant Valley Medical Center. The Company filed post-judgment motions for a new trial, which were denied, and intends to vigorously pursue an appeal of the judgment on multiple grounds. The Company carries self-insurance reserves and excess liability insurance sufficient to cover the potential liability in this case.

Under the Company’s present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers’ compensation. The self-insured retentions are on a per occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company’s estimates of the aggregated liability of claims incurred. At December 31, 2013, the Company had provided letters of credit aggregating approximately $42.5, primarily in connection with certain insurance programs. The Company’s availability under its Revolving Credit Facility is reduced by the amount of these letters of credit.

The Company leases various facilities and equipment under non-cancelable lease arrangements. Future minimum rental commitments for leases with non-cancelable terms of one year or more at December 31, 2013 are as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Minimum Operating Lease Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$132.3</td>
</tr>
<tr>
<td>2015</td>
<td>81.8</td>
</tr>
<tr>
<td>2016</td>
<td>58.1</td>
</tr>
<tr>
<td>2017</td>
<td>39.7</td>
</tr>
<tr>
<td>2018</td>
<td>20.5</td>
</tr>
<tr>
<td>Thereafter</td>
<td>41.0</td>
</tr>
</tbody>
</table>

Total minimum lease payments: $373.4
Less: amounts included in restructuring and acquisition related accruals: (12.4)
Non-cancelable sub-lease income: –
Total minimum operating lease payments: $361.0

Rental expense, which includes rent for real estate, equipment and automobiles under operating leases, amounted to $235.7, $226.0 and $220.2 for the years ended December 31, 2013, 2012 and 2011, respectively.

16. Pension and Postretirement Plans

Pension Plans

The Company has a defined benefit retirement plan (the “Company Plan”) and a nonqualified supplemental retirement plan (the “PEP”). Both plans have been closed to new participants since December 31, 2009. Employees participating in the Company Plan and the PEP no longer earn service-based credits, but continue to earn interest credits. In addition, effective January 1, 2010, all employees eligible for the defined contribution retirement plan (the “401K Plan”) receive a minimum 3% non-elective contribution (“NEC”) concurrent with each payroll period. Employees are not required to make a contribution to the 401K Plan to receive the NEC. The NEC is non-forfeitable and vests immediately. The 401K Plan also permits discretionary contributions by the Company of 1% to 3% of pay for eligible employees based on service.

The Company’s 401K Plan covers substantially all employees. Prior to 2010, Company contributions to the plan were based on a percentage of employee contributions. In 2013, 2012 and 2011, the Company made non-elective and discretionary contributions
to the plan. Non-elective and discretionary contributions were $49.4, $49.0 and $44.3 in 2013, 2012 and 2011, respectively.

In addition, the Company Plan covers substantially all employees hired prior to December 31, 2009. The benefits to be paid under the Company Plan are based on years of credited service through December 31, 2009, interest credits and average compensation. The Company’s policy is to fund the Company Plan with at least the minimum amount required by applicable regulations. The Company made contributions to the Company Plan of $8.4, $11.3 and $0.0 in 2013, 2012 and 2011, respectively.

The PEP covers the Company’s senior management group. Prior to 2010, the PEP provided for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan but for such limitation. Effective January 1, 2010, employees participating in the PEP no longer earn service-based credits. The PEP is an unfunded plan.

Projected pension expense for the Company Plan and the PEP is expected to decrease to $7.8 in 2014. This amount excludes any accelerated recognition of pension cost due to the total lump-sum payouts exceeding certain components of net periodic pension cost in a fiscal year. If such levels were to be met in 2014, the Company projects that it would result in an additional $6.4 of pension expense.

The Company plans to make contributions of $11.0 to the Company Plan during 2014.

A summary of the changes in the projected benefit obligations of the Company Plan and the PEP are summarized as follows:

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service cost for benefits earned</td>
<td>$3.1</td>
<td>$2.4</td>
</tr>
<tr>
<td>Interest cost on benefit obligation</td>
<td>14.7</td>
<td>14.9</td>
</tr>
<tr>
<td>Expected return on plan assets</td>
<td>(17.3)</td>
<td>(17.3)</td>
</tr>
<tr>
<td>Net amortization and deferral</td>
<td>10.5</td>
<td>12.1</td>
</tr>
<tr>
<td>Defined benefit plan costs</td>
<td>$11.0</td>
<td>$12.1</td>
</tr>
</tbody>
</table>

The Accumulated Benefit Obligation was $349.7 and $380.7 at December 31, 2013 and 2012, respectively.

A summary of the changes in the fair value of plan assets follows:

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value of plan assets at beginning of year</td>
<td>$256.8</td>
<td>$246.5</td>
</tr>
<tr>
<td>Actual return on plan assets</td>
<td>28.1</td>
<td>25.0</td>
</tr>
<tr>
<td>Employer contributions</td>
<td>9.9</td>
<td>12.9</td>
</tr>
<tr>
<td>Benefits and administrative expenses paid</td>
<td>(26.7)</td>
<td>(25.6)</td>
</tr>
<tr>
<td>Fair value of plan assets at end of year</td>
<td>$268.1</td>
<td>$256.8</td>
</tr>
</tbody>
</table>

The net funded status of the Company Plan and the PEP at December 31:

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funded status</td>
<td>$81.6</td>
<td>$123.9</td>
</tr>
<tr>
<td>Recorded as:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accrued expenses and other</td>
<td>$1.6</td>
<td>$1.4</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>80.0</td>
<td>122.5</td>
</tr>
<tr>
<td>Total</td>
<td>$81.6</td>
<td>$123.9</td>
</tr>
</tbody>
</table>

Weighted average assumptions used in the accounting for the Company Plan and the PEP are summarized as follows:

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discount rate</td>
<td>4.8%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Expected long-term rate of return</td>
<td>7.0%</td>
<td>7.0%</td>
<td>7.3%</td>
</tr>
</tbody>
</table>

The Company maintains an investment policy for the management of the Company Plan's assets. The objective of this policy is to build a portfolio designed to achieve a balance between investment return and asset protection by investing in indexed funds that are comprised of equities of high-quality companies and in high-quality fixed income securities which are broadly balanced and represent all market sectors. The target allocations for plan assets are 50% equity securities, 45% fixed income securities and 5% in other assets. Equity securities primarily include investments in large-cap, mid-cap and small-cap companies located in the U.S. and to a lesser extent international equities in developed and emerging countries. Fixed income securities primarily include U.S. Treasury securities, mortgage-backed bonds and corporate bonds.
of companies from diversified industries. Other assets include investments in commodities. The weighted average expected long-term rate of return for the Company Plan’s assets is as follows:

<table>
<thead>
<tr>
<th></th>
<th>Target Allocation</th>
<th>Weighted Average Expected Long-Term Rate of Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity securities</td>
<td>50.0%</td>
<td>5.5%</td>
</tr>
<tr>
<td>Fixed income securities</td>
<td>45.0%</td>
<td>1.2%</td>
</tr>
<tr>
<td>Other assets</td>
<td>5.0%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

The fair values of the Company Plan’s assets at December 31, 2013 and 2012, by asset category are as follows:

<table>
<thead>
<tr>
<th>Asset Category</th>
<th>2013 Fair Value</th>
<th>2012 Fair Value</th>
<th>Fair Value Measurements as of December 31, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>$2.7</td>
<td>$6.9</td>
<td>Level 1 Level 2 Level 3</td>
</tr>
<tr>
<td>Equity securities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. large cap – blend(^a)</td>
<td>65.5</td>
<td>58.1</td>
<td></td>
</tr>
<tr>
<td>U.S. mid cap – blend(^b)</td>
<td>23.2</td>
<td>23.2</td>
<td></td>
</tr>
<tr>
<td>U.S. small cap – blend(^c)</td>
<td>8.1</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>International equity – blend(^d)</td>
<td>40.3</td>
<td>39.4</td>
<td></td>
</tr>
<tr>
<td>Commodity index(^e)</td>
<td>11.3</td>
<td>11.3</td>
<td></td>
</tr>
<tr>
<td>Fixed income securities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. fixed income(^f)</td>
<td>104.1</td>
<td>104.1</td>
<td></td>
</tr>
<tr>
<td>U.S. inflation protection income(^g)</td>
<td>11.0</td>
<td>11.0</td>
<td></td>
</tr>
<tr>
<td>Total fair value of the Company Plan’s assets</td>
<td>$268.1</td>
<td>$256.8</td>
<td></td>
</tr>
</tbody>
</table>

The following assumed benefit payments under the Company Plan and PEP which were used in the calculation of projected benefit obligations, are expected to be paid as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$23.4</td>
</tr>
<tr>
<td>2014</td>
<td>$23.4</td>
</tr>
<tr>
<td>2015</td>
<td>$23.5</td>
</tr>
<tr>
<td>2016</td>
<td>$23.3</td>
</tr>
<tr>
<td>2017</td>
<td>$23.4</td>
</tr>
<tr>
<td>Years 2018-2022</td>
<td>$120.5</td>
</tr>
</tbody>
</table>

### Post-retirement Medical Plan

The Company assumed obligations under a subsidiary’s post-retirement medical plan. Coverage under this plan is restricted to a limited number of existing employees of the subsidiary. This plan is unfunded and the Company’s policy is to fund benefits as claims are incurred. The effect on operations of the post-retirement medical plan is shown in the following table:

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service cost for benefits earned</td>
<td>$0.4</td>
<td>$0.4</td>
<td>$0.3</td>
</tr>
<tr>
<td>Interest cost on benefit obligation</td>
<td>2.5</td>
<td>2.2</td>
<td>2.2</td>
</tr>
<tr>
<td>Net amortization and deferral</td>
<td>1.0</td>
<td>0.3</td>
<td>(0.2)</td>
</tr>
<tr>
<td>Post-retirement medical plan costs</td>
<td>$3.9</td>
<td>$3.0</td>
<td>$2.3</td>
</tr>
</tbody>
</table>

Amounts included in accumulated other comprehensive earnings consist of unamortized net loss of $12.7. The accumulated other comprehensive earnings that are expected to be recognized as components of the post-retirement medical plan costs during 2014 are $1.3 related to amortization of the net loss.

A summary of the changes in the accumulated post-retirement benefit obligation follows:

<table>
<thead>
<tr>
<th>Balance as of December 31</th>
<th>2013 $60.7</th>
<th>2012 $52.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service cost for benefits earned</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Interest cost on benefit obligation</td>
<td>2.5</td>
<td>2.2</td>
</tr>
<tr>
<td>Participants contributions</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Actuarial loss</td>
<td>4.5</td>
<td>6.9</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(2.7)</td>
<td>(2.0)</td>
</tr>
<tr>
<td>Plan amendment</td>
<td>(3.0)</td>
<td></td>
</tr>
<tr>
<td>Balance as of December 31</td>
<td>$62.7</td>
<td>$60.7</td>
</tr>
</tbody>
</table>

Recorded as:

Other liabilities | $62.7 | $60.7 |
The weighted-average discount rates used in the calculation of the accumulated post-retirement benefit obligation were 5.0% and 4.2% as of December 31, 2013 and 2012, respectively. The health care cost trend rate was assumed to be 7.5% as of December 31, 2013 and 2012, declining gradually to 5.0% in the year 2021. The health care cost trend rate has a significant effect on the amounts reported. The impact of a percentage point change each year in the assumed health care cost trend rates would change the accumulated post-retirement benefit obligation as of December 31, 2013 by an increase of $8.7 or a decrease of $7.3. The impact of a percentage point change on the aggregate of the service cost and interest cost components of the 2013 post-retirement benefit costs results in an increase of $0.5 or decrease of $0.4. The plan amendment in 2013 reflects the impact of shifting from projection scale AA to projection scale BB for both the RP-2000 Combined Healthy Mortality Table and the RP-2000 Disabled Mortality Table.

The following assumed benefit payments under the Company’s post-retirement benefit plan, which reflect expected future service, as appropriate, and were used in the calculation of projected benefit obligations, are expected to be paid as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$2.5</td>
</tr>
<tr>
<td>2015</td>
<td>2.7</td>
</tr>
<tr>
<td>2016</td>
<td>2.9</td>
</tr>
<tr>
<td>2017</td>
<td>3.0</td>
</tr>
<tr>
<td>2018</td>
<td>3.1</td>
</tr>
<tr>
<td>Years 2019-2023</td>
<td>17.9</td>
</tr>
</tbody>
</table>

**Deferred Compensation Plan**

In 2001, the Board approved the Deferred Compensation Plan ("DCP") under which certain of the Company’s executives, may elect to defer up to 100.0% of their annual cash incentive pay and/or up to 50.0% of their annual base salary and/or eligible commissions subject to annual limits established by the federal government. The DCP provides executives a tax efficient strategy for retirement savings and capital accumulation without significant cost to the Company. The Company makes no contributions to the DCP. Amounts deferred by a participant are credited to a bookkeeping account maintained on behalf of each participant, which is used for measurement and determination of amounts to be paid to a participant, or his or her designated beneficiary, pursuant to the terms of the DCP. The amounts accrued under this plan were $36.3 and $26.6 at December 31, 2013 and 2012, respectively. Deferred amounts are the Company’s general unsecured obligations and are subject to claims by the Company’s creditors. The Company’s general assets may be used to fund obligations and pay DCP benefits.

**17. Fair Value Measurements**

The Company’s population of financial assets and liabilities subject to fair value measurements as of December 31, 2013 and 2012 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Fair Value as of December 31, 2013</th>
<th>Fair Value Measurements as of December 31, 2013 Using Fair Value Hierarchy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 2</td>
</tr>
<tr>
<td>Noncontrolling interest put</td>
<td>$19.4</td>
<td>$ –</td>
</tr>
<tr>
<td>Interest rate swap</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cash surrender value of life insurance policies</td>
<td>35.1</td>
<td>–</td>
</tr>
<tr>
<td>Deferred compensation liability</td>
<td>36.3</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Fair Value as of December 31, 2012</th>
<th>Fair Value Measurements as of December 31, 2012 Using Fair Value Hierarchy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 2</td>
</tr>
<tr>
<td>Noncontrolling interest put</td>
<td>$20.7</td>
<td>$ –</td>
</tr>
<tr>
<td>Cash surrender value of life insurance policies</td>
<td>30.4</td>
<td>–</td>
</tr>
<tr>
<td>Deferred compensation liability</td>
<td>26.6</td>
<td>–</td>
</tr>
</tbody>
</table>

The noncontrolling interest put is valued at its contractually determined value, which approximate fair value. During the year ended December 31, 2013, the carrying value of the noncontrolling interest put decreased by $1.3 consisting of a $0.8 increase in the contractually determined value and a $2.5 decrease for foreign currency translation.

The Company offers certain employees the opportunity to participate in a DCP. A participant’s deferrals are "invested" at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. From time to time, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.
The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the zero-coupon subordinated notes, based on market pricing, was approximately $155.5 and $179.1 as of December 31, 2013 and 2012, respectively. The fair market value of the senior notes, based on market pricing, was approximately $2,907.8 and $2,720.5 as of December 31, 2013 and 2012, respectively. The Company’s note and debt instruments are considered level 2 instruments, as the fair market values of these instruments are determined using other observable inputs. The Company’s investment in equity securities of $16.4 is considered a level 1 instrument, as the fair market value of this instrument is determined using observable inputs.

18. Derivative Instruments and Hedging Activities
The Company addresses its exposure to market risks, principally the market risk associated with changes in interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as interest rate swap agreements (see Interest Rate Swap section below). Although the Company’s zero-coupon subordinated notes contain features that are considered to be embedded derivative instruments (see Embedded Derivative section below), the Company does not hold or issue derivative financial instruments for trading purposes. The Company does not believe that its exposure to market risk is material to the Company’s financial position or results of operations.

Interest Rate Swap
During the third quarter of 2013, the Company entered into two fixed-to-variable interest rate swap agreements for the 4.625% senior notes due 2020 with an aggregate notional amount of $600.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company’s long-term debt. These derivative financial instruments are accounted for as fair value hedges of the senior notes due 2020. These interest rate swaps are included in other long-term assets or liabilities, as applicable, and added to the value of the senior notes, with an aggregate fair value of $0.0 at December 31, 2013. As the specific terms and notional amounts of the derivative financial instruments match those of the fixed-rate debt being hedged, the derivative instruments are assumed to be perfectly effective hedges and accordingly, there is no impact to the Company’s consolidated statements of operations. Cash flows from the interest rate swaps are included in operating activities. There were no derivative instruments designated as accounting hedges in 2012.

Embedded Derivatives Related to the Zero-Coupon Subordinated Notes
The Company’s zero-coupon subordinated notes contain the following two features that are considered to be embedded derivative instruments under authoritative guidance in connection with accounting for derivative instruments and hedging activities:

1) The Company will pay contingent cash interest on the zero-coupon subordinated notes after September 11, 2006, if the average market price of the notes equals 120% or more of the sum of the issue price, accrued original issue discount and contingent additional principal, if any, for a specified measurement period.
2) Holders may surrender zero-coupon subordinated notes for conversion during any period in which the rating assigned to the zero-coupon subordinated notes by Standard & Poor’s Ratings Services is BB- or lower.

The Company believes these embedded derivatives had no fair value at December 31, 2013 and 2012. These embedded derivatives also had no impact on the consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011.
19. Supplemental Cash Flow Information

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash paid during period for:</td>
<td>$ 97.2</td>
<td>$ 77.5</td>
<td>$ 99.6</td>
</tr>
<tr>
<td>Interest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income taxes, net of refunds</td>
<td>301.5</td>
<td>306.2</td>
<td>309.4</td>
</tr>
<tr>
<td>Disclosure of non-cash financing and investing activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surrender of restricted stock awards and performance shares</td>
<td>7.1</td>
<td>10.9</td>
<td>6.0</td>
</tr>
<tr>
<td>Conversion of zero-coupon convertible debt</td>
<td>10.3</td>
<td>3.8</td>
<td>36.2</td>
</tr>
<tr>
<td>Assets acquired under capital leases</td>
<td>13.1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Accrued property, plant and equipment</td>
<td>9.1</td>
<td>1.2</td>
<td>–</td>
</tr>
</tbody>
</table>

20. Business Segment Information

The following table is a summary of segment information for the years ended December 31, 2013, 2012, and 2011. Segment asset information is not presented because it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses are included in general corporate expenses below.

Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. Clinical diagnostics laboratory segment includes financial information related to the broad range of testing services that are reported primarily through the U.S. business operations.

The other reportable segment includes the Company’s non-U.S. clinical diagnostic laboratory operations in Ontario, Canada, which are reviewed separately by corporate management for the purposes of allocation of resources.
21. Quarterly Data (Unaudited)

The following is a summary of unaudited quarterly data:

<table>
<thead>
<tr>
<th>Year Ended December 31, 2013</th>
<th>1st Quarter</th>
<th>2nd Quarter</th>
<th>3rd Quarter</th>
<th>4th Quarter</th>
<th>Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$1,440.9</td>
<td>$1,468.2</td>
<td>$1,462.2</td>
<td>$1,437.0</td>
<td>$5,808.3</td>
</tr>
<tr>
<td>Gross profit</td>
<td>572.2</td>
<td>577.3</td>
<td>547.6</td>
<td>526.1</td>
<td>2,223.2</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>147.2</td>
<td>151.9</td>
<td>148.3</td>
<td>126.4</td>
<td>573.8</td>
</tr>
<tr>
<td>Basic earnings per common share</td>
<td>1.58</td>
<td>1.65</td>
<td>1.66</td>
<td>1.46</td>
<td>6.36</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>1.56</td>
<td>1.62</td>
<td>1.63</td>
<td>1.43</td>
<td>6.25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year Ended December 31, 2012</th>
<th>1st Quarter</th>
<th>2nd Quarter</th>
<th>3rd Quarter</th>
<th>4th Quarter</th>
<th>Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>$1,423.3</td>
<td>$1,423.4</td>
<td>$1,419.4</td>
<td>$1,405.3</td>
<td>$5,671.4</td>
</tr>
<tr>
<td>Gross profit</td>
<td>576.1</td>
<td>579.5</td>
<td>556.1</td>
<td>538.0</td>
<td>2,249.7</td>
</tr>
<tr>
<td>Net earnings attributable to Laboratory Corporation of America Holdings</td>
<td>161.6</td>
<td>153.3</td>
<td>148.0</td>
<td>120.2</td>
<td>583.1</td>
</tr>
<tr>
<td>Basic earnings per common share</td>
<td>1.66</td>
<td>1.59</td>
<td>1.56</td>
<td>1.28</td>
<td>6.09</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>1.63</td>
<td>1.56</td>
<td>1.53</td>
<td>1.26</td>
<td>5.99</td>
</tr>
</tbody>
</table>
Shareholder and Company Information

Corporate Headquarters
358 South Main Street
Burlington, NC 27215
336-584-5171

Information Sources
Information about LabCorp is available from the following Company sources:
Investor Relations Contact
Stephen Anderson
Vice President, Investor Relations
336-436-5076
Center for Molecular Biology and Pathology
800-345-4363
Center for Occupational Testing
800-833-345
Center for Esoteric Testing
800-343-5176
Paternity/Identity
800-582-0077
LabCorp Drug Development Laboratory Services
877-788-8861
Website
www.labcorp.com

Transfer Agent
American Stock Transfer & Trust Company
Shareholder Services
6201 Fifteenth Avenue
Brooklyn, NY 11219
800-937-5449
www.amstock.com

Independent Registered Public Accounting Firm
PricewaterhouseCoopers LLP
800 Green Valley Road, Suite 500
Greensboro, NC 27408

Annual Meeting
The annual meeting of shareholders will be held at 9:00 a.m. EDT on May 14, 2014 at the Paramount Theater, 128 East Front Street, Burlington, NC 27215.

Form 10-K
Copies of Form 10-K as filed with the Securities and Exchange Commission are available without cost to shareholders by writing to: Laboratory Corporation of America Holdings, Investor Relations Department, 358 South Main Street, Burlington, NC 27215.

Safe Harbor
Forward-looking statements in this annual report are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors which could affect the Company’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2013, and subsequent filings.

Common Stock
The Company’s common stock, par value $0.10 per share (the “Common Stock”), trades on the New York Stock Exchange (“NYSE”) under the symbol “LH.” The following table sets forth the high and low sales prices for the Common Stock reported on the NYSE Composite Tape.

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>1Q</td>
<td>$91.84</td>
<td>$85.80</td>
</tr>
<tr>
<td>2Q</td>
<td>$101.69</td>
<td>$89.68</td>
</tr>
<tr>
<td>3Q</td>
<td>$101.92</td>
<td>$95.36</td>
</tr>
<tr>
<td>4Q</td>
<td>$108.00</td>
<td>$87.01</td>
</tr>
</tbody>
</table>

Corporate Governance, Code of Business Conduct and Ethics
The Company’s Corporate Governance Guidelines, the Charters of its Audit Committee, Compensation Committee, Quality and Compliance Committee, and Nominating and Corporate Governance Committee as well as the Company’s Code of Business Conduct and Ethics are available on the Company’s website at www.labcorp.com. You can also obtain a hard copy of these documents, without charge, upon written request to Stephen Anderson, Laboratory Corporation of America Holdings, 358 South Main Street, Burlington, NC 27215.

Board of Directors
David P. King
Chairman and Chief Executive Officer

Kenrii B. Anderson 1,2
Former Chief Executive Officer and President of Wendy’s International, Inc.

Jean-Luc Bélingard 2,3
Chairman, bioMérieux S.A.; retired Chairman and CEO, Ipsen S.A.

Garheng Kong, M.D., Ph.D.
General Partner at Sofinnova HealthQuest

Wendy E. Lane 1,4
Chairman of Lane Holdings, Inc., an investment firm

Robert E. Mittelstaedt, Jr. 1,4
Dean Emeritus of the W. P. Carey School of Business at Arizona State University

Peter M. Neuport 2,4
Operating Partner at Health Evolution Partners

Arthur H. Rubenstein, MB BCH 1,4
Professor of Medicine
University of Pennsylvania
Pennie School of Medicine

Adam H. Schechter 1,2
Executive Vice President of Merck & Co., Inc. and the President of Merck’s Global Human Health Division

M. Keith Weikel, Ph.D. 1,2,3
Former Senior Executive Vice President and Chief Operating Officer of HCR Manor Care, Inc.

R. Sanders Williams, M.D. 1,2
President of The J. David Gladstone Institutes and Professor of Medicine at The University of California San Francisco

Committees:
1 Audit
2 Compensation
3 Quality and Compliance
4 Nominating and Corporate Governance

Management Team
David P. King, Chairman and Chief Executive Officer
James T. Boyle, Executive Vice President and Chief Operating Officer
William B. Hayes, Executive Vice President and Chief Financial Officer
Lance V. Berberian, Senior Vice President and Chief Information Officer
Mark E. Brecher, M.D., Senior Vice President and Chief Medical Officer
F. Samuel Eberts III, Senior Vice President and Chief Legal Officer
Adam T. Feinstein, Senior Vice President, Corporate Development & Strategic Planning
Lisa Hoffman Starr, Senior Vice President, Human Resources